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 “When things go wrong, as they sometimes will; 
When the road you´re trudging seems all uphill; 
When the funds are low and the debts are high; 
And you want to smile but you have to sign. 
When all is pressing you down a bit –  
Rest if you must, but don´t you quit. 
Success is failure turned inside out; 
The silver tint on the clouds of doubt; 
And you can never tell how close you are; 
It may be near when it seems far. 
So stick to the fight when you´re hardest hit –  
It´s when things go wrong that you must not quit.” 
  
 – John Greenleaf Whittier 
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Abstract 
There is accumulating evidence that Alzheimer´s Disease (AD) pathogenesis correlates with increased 
oxidative stress due to the overproduction of reactive oxygen species (ROS) and decrease in antioxidant 
defense systems. Several cellular insults increasing oxidative stress in AD include mitochondrial 
dysfunction, inflammation and the accumulation of oxidative stress markers. Developing genetic in vivo 
models to study the impact of redox homeostasis on amyloid-beta (Aβ) neurotoxicity and to decipher 
whether changes in redox balance are a cause or consequence of AD pathology is of high importance.  
Here, I present ‘newly established’ in vivo models to study the role of redox homeostasis in AD. Therefore, 
I combine genetically encoded redox sensors with Drosophila models of Aβ aggregation. Thereby, I focus 
on two major regulators of the redox homeostasis. On the one hand, hydrogen peroxide (H2O2), a non-
radical oxidant and major ROS that possesses cytotoxic effects and is an important signaling molecule. 
And on the other hand, I focus on glutathione, a low molecular weight thiol, which represents one of the 
two major Nicotinamide adenine dinucleotide phosphate (NADPH)-dependent reducing systems in the 
cell that holds protective effects against oxidative damage. In this thesis, I aim to provide new insights into 
a better characterization and understanding of the impact of changes in redox homeostasis and the 
involvement of stress responsive pathways in the onset and progression of AD.  
The main finding of this study is that changes in glutathione redox potential are linked to Aβ42 
neurotoxicity. I have found that the common notion of ‘oxidative stress‘ driven neurodegeneration is 
specifically mediated by changes in the neuronal glutathione redox potential rather than the increasing 
levels of H2O2. Interestingly, neurons respond to the deposition of Aβ42 by an increase in glutathione 
redox potential but glia cells are not susceptible for this insult caused by toxic Aβ42. The glutathione redox 
imbalance already occurs at an early time point of Aβ deposition and is only observable in toxic Aβ42-
expressing flies but not in flies expressing the less toxic TandemAβ40 variant. Most notably, I show that 
modifications of glutathione synthesis directly modulate Aβ42-mediated neurotoxicity, in parallel to an 
increase in the c-Jun N-terminal kinase (JNK) stress signaling response. Intriguingly, an increase in 
glutathione synthesis is not beneficial in this AD disease model, but exacerbates Aβ42-mediated toxicity. 
While recent studies point towards the important role of redox signaling processes being the driving force 
in many human diseases, main novelty of this thesis is the development of genetic in vivo tools to 
selectively analyze changes in redox homeostasis associated with AD pathomechanisms. To summarize, I 
hereby provide in vivo evidence of the central role of glutathione redox homeostasis in early AD 
pathogenesis and progression. Furthermore, I examine early events of neuronal dysregulation and disease 
onset and further offer a screening platform for possible disease modifying therapies. Most importantly, 
this study proposes additional roles of glutathione beyond the generic neuroprotective antioxidant and 
being involved in the Aβ42-induced neurotoxicity.  
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Zusammenfassung 
Viele Belege weisen darauf hin, dass die Entstehung der Alzheimer Erkrankung mit einem erhöhten 
Auftreten von oxidativem Stress einhergeht. Oxidativer Stress wird durch eine Überproduktion von 
reaktiven Sauerstoffspezies oder durch eine Verminderung von anti-oxidativen Abwehrsystemen 
verursacht. Mehrere zelluläre Prozesse können zu einem erhöhten oxidativen Stress beitragen. Dazu zählen 
eine Fehlfunktion der Mitochondrien, Entzündungsprozesse und die Anhäufung von oxidativen 
Stressmarkern. Die Entwicklung von genetischen Modellen im lebenden Organismus ist daher von 
größter Wichtigkeit um den Einfluss der Redox-Homöostase auf die Neurotoxizität von Amyloid-beta 
(Aβ) zu untersuchen und zu entschlüsseln, ob Veränderungen des Redox-Gleichgewichtes die Ursache 
oder Konsequenz der Alzheimer Pathologie sind. Ich präsentiere hier neu etablierte in vivo Modelle um die 
Rolle der Redox-Homöostase in der Alzheimer Erkrankung zu untersuchen. Dafür kombiniere ich 
genetisch kodierte Redox-Sensoren mit Drosophila Modellen der Aβ-Aggregation. Dabei konzentriere ich 
mich auf zwei Hauptregulatoren der Redox-Homöostase. Einerseits Wasserstoffperoxide (H2O2), ein 
nicht-radikales Oxidans und Haupt-reaktives-Sauerstoffspezies, welches zellschädigende Wirkungen besitzt 
und ein wichtiges Signalmolekül darstellt. Andererseits konzentriere ich mich auf Glutathion, ein Thiol 
mit niedrigem Molekulargewicht, welches eines der zwei wesentlichen Nicotinamideadenindinukleotid-
phosphat (NADPH)-abhängigen Reduktionssysteme in der Zelle darstellt und gegen oxidative Schäden 
schützt. Ziel der Studie ist es neue Einblicke in eine bessere Charakterisierung und in ein besseres 
Verständnis der Auswirkungen von Redox-Homöostase-Veränderungen zu geben. Ein weiteres Ziel ist es 
neue Erkenntnisse der Beteiligung von Stress-Signalwegen zu Beginn und während des 
Krankheitsverlaufes der Alzheimer Erkrankung zu gewinnen. 
Die Kernaussage der Studie ist, dass Veränderungen des Glutathione-Redoxpotentials mit der 
Neurotoxizität von Aβ42 verknüpft sind. Ich habe herausgefunden, dass die allgemeine Grundauffassung 
von durch ‘oxidativem Stress’-induzierte Neurodegeneration, eher spezifisch durch Veränderungen des 
Glutathione-Redoxpotentials als durch steigende H2O2 Konzentrationen vermittelt wird. 
Interessanterweise reagieren Neuronen auf die Ablagerungen von toxischem Aβ42 durch eine Erhöhung des 
Glutathione-Redoxpotentials. Jedoch sind Gliazellen durch diesen durch Aβ42 verursachten toxischen 
Schaden nicht anfällig. Bereits zu einem frühen Zeitpunkt der Aβ-Ablagerung tritt ein Glutathion-Redox-
Ungleichgewicht auf. Diese ist nur in Fliegen zu beobachten, die eine toxische Aβ42-Variante, nicht jedoch 
eine weniger toxische TandemAβ40-Variante exprimieren. Insbesondere zeige ich, dass Modifikationen der 
Glutathion-Synthese die Aβ42-vermittelte Neurotoxizität direkt modulieren, und parallel zu einer 
Zunahme der c-Jun-N-terminale Kinasen (JNK)-Stresssignalantwort führen. Interessanterweise ist eine 
erhöhte Glutathion-Synthese in diesem Alzheimer-Krankheitsmodell nicht von Vorteil, sondern 
verschlimmert sogar die Aβ42-vermittelte Toxizität. Während jüngste Studien auf die wichtige Rolle von 
vi 
Redox-Signalprozessen als treibende Kraft bei vielen menschlichen Erkrankungen hindeuten, besteht die 
Hauptneuheit dieser Arbeit in der Entwicklung genetischer in-vivo-Werkzeuge zur selektiven Analyse von 
Veränderungen der Redox-Homöostase die in Zusammenhang mit AD-Pathomechanismen stehen. 
Zusammenfassend liefere ich in vivo Beweise der zentralen Rolle der Glutathion-Redox-Homöostase in 
der frühen Krankheitsentstehung und im Krankheitsverlauf der Alzheimer Erkrankung. Darüber hinaus 
untersuche ich frühe Ereignisse neuronaler Dysregulation und Krankheitsbeginn und biete eine Screening-
Plattform für mögliche krankheitsmodifizierende Therapien. Glutathion ist bekannt als neuroprotektives 
Antioxidans. Diese Studie zeigt auf, dass Glutathione auch zusätzliche Rollen besitzt und an der Aβ42-
induzierten Neurotoxizität beteiligt ist. 
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1.  Introduction 
1.1 Alzheimer´s disease (AD) 
Alzheimer´s disease (AD) is a fatal neurodegenerative disease and the most prevalent type of age-related 
dementia. Approximately 47 million people are suffering from AD or a related dementia worldwide, with 
1.5 million people in Germany alone (Holtzman et al. 2011), (Alzheimer´s Disease International 
https://www.alz.co.uk/research/statistics). According to the Alzheimer´s Association and Alzheimer´s 
Disease International the number of people suffering from AD and dementia will dramatically increase 
within the next decades, with estimated numbers of 131.5 million people in 2050. Clinical symptoms of 
diagnosed AD patients include gradual memory loss and other cognitive dysfunctions (Aguzzi & 
O’Connor 2010; De Strooper & Karran 2016). As the disease slowly progresses affected people experience 
personality and behavioral changes, decline in language, and the loss of the ability to memorize as well as 
to recall newly learned information. Finally, also long-term memory will be affected. The occurring brain 
damage due to detrimental loss of neurons mostly affect the hippocampus, the association areas of the 
cerebral cortex and the subcortical brain regions (Serrano-Pozo et al. 2011; Goedert et al. 1991).  
While the typical life expectancy after diagnosis is 4-8 years (Alzheimer´s Association, 
http://www.alzheimers.net/resources/alzheimers-statistics/), the processes and brain changes initiating the 
disease pathology are believed to start decades before the occurrence of any clinically detectable symptoms 
occur (von Bernhardi & Eugenín 2012; Bermejo et al. 2008). The methods for diagnosing AD, e.g. using 
amyloid PET imaging, improved within the last years (Mallik et al. 2017; de Wilde et al. 2017). This 
helps building better treatment plans for a more customized individual therapy, compared to earlier days, 
where a distinct diagnosis of AD could only be secured by post-mortem examinations of the patients brain 
(McKhann et al. 1984; Rosén et al. 2013). Until now, there is still no cure or therapy available to slowing-
down the progressive brain damage and dementia caused by this neurodegenerative disease. Investigating 
early stages of this disease is therefore important for identifying potential targets and developing new 
treatments. 
 
 
1.1.1  Molecular hal lmarks of  AD 
The first person described with symptoms of the disease, which was later called Alzheimer´s Disease, was 
Auguste Deter in 1907. Emil Kraepelin, who was the director of the Royal Psychatric Clinic in Munic 
named the disease after Alois Alzheimer, who observed the combined presence of the two stereotypic 
pathological hallmarks of AD, plaques and tangles, from her examined post-mortem brain, using a 
reduced silver staining technique (Goedert 2009; Alzheimer 1907). In that same year, another psychiatrist 
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and neuropathologist Oskar Fischer contributed to the present definition of these hallmarks, when he for 
the first time described the neuritic plaque by examining 16 cases of senile dementia (Goedert 2009). 
As briefly mentioned above, the two pathological hallmarks of AD are the abnormal deposition of 
intracellular neurofibrillary tangles (NFTs) and extracellular senile plaques, consisting of two distinct 
aggregated proteins, namely hyperphosphorylated tau (Goedert et al. 1991; Mandelkow 2012) and 
amyloid beta (Aβ) (John Hardy & Allsop 1991; Holtzman et al. 2011). Tau is a microtubule-binding 
protein and mainly localized in neuronal axons (Weingarten et al. 1975). Under physiological conditions 
tau promotes the assembly and stabilization of microtubules. It is rich of serine and threonine residues, 
making it a target for several kinases including GSK3β and ERK (Aguzzi & O’Connor 2010), which 
under abnormal conditions are causing its hyperphosphorylation, leading to its vulnerability to aggregate, 
resulting in its detachment from microtubules and consequently destabilizing the microtubule network 
(Grundke-Iqbal et al. 1987; Götz & Ittner 2008). The disrupted microtubule network then contributes to 
neuronal dysfunction including axonal degeneration, disruption of axonal transport and sequestering of 
proteins and cell death (Aguzzi & O’Connor 2010; Dawson et al. 2010).  
The second abnormal depositions that can be found in AD patients are extracellular senile plaques mainly 
consisting of misfolded and aggregated Aβ. Aβ is produced in the brain throughout life and accumulates 
during aging in the cerebral cortex, which under pathologic conditions such as in AD, can lead to the 
excessive deposition of Aβ (John Hardy & Allsop 1991; Aguzzi & O’Connor 2010). A stereotypic 
spreading of Aβ pathology throughout the brain has been observed in AD patients, where senile plaques 
first occur in the neocortex, next in the allocortex and eventually progress to subcortical regions (Thal et 
al. 2002; Jucker & Walker 2013). Its amyloid precursor protein (APP) is an integral membrane protein 
and is expressed in several tissues, but much higher in the brain (Nalivaeva & Turner 2013). APP has been 
linked to synapse formation and activity (Priller et al. 2006), iron export (Duce et al. 2010) and neuronal 
plasticity (Turner et al. 2003). A number of physiological functions of Aβ have been described, including 
the maintenance of the structural integrity of the blood brain barrier (BBB) (Atwood et al. 2003), the 
involvement in Ca2+ signaling (Smith et al. 2004; Pearson & Peers 2006) and its antioxidant properties at 
low concentrations due to its metal binding sites and its ability to act as metal chelator capturing metals, 
such as Fe, Cu and Zn which prevents this potentially redox active species from participation in oxidative 
reactions (Pearson & Peers 2006; Atwood et al. 2003).  
Aβ is generated through the amyloidogenic pathway and is derived from proteolytic cleavage of the APP 
by distinct secretases. This processing of the integral membrane protein APP, which takes place in the 
endosome (Rajendran & Annaert 2012), includes its initial proteolytic cleavage by the β-secretase, 
followed by the γ-secretase cleavage and resulting in the release of the Aβ peptide. In the initial step, the β-
secretase cleaves off the N-terminal part of the APP, giving rise to APPsβ and C99. Then, depending on 
the position of the γ-secretase cleavage within the C99, the APP intracellular domain (AICD) and 
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different lengths of Aβ (38-43 amino acids) are formed (Hardy 1997; Aguzzi & O’Connor 2010). The 
most common forms of the Aβ peptide are the forty and forty-two amino acid long Aβ40 and Aβ42, which 
differ in their neurotoxicity levels. Aβ42 has been identified as the highly aggregation prone and neurotoxic 
factor in AD, and because of its higher rate of fibrillization and insolubility, Aβ42 is much more abundant 
within senile plaques than Aβ40. In contrast, due to its low aggregation susceptibility, lacking the two 
additional unpolar amino acids (C-terminal Isoleucin and Alanin) Aβ40 possesses a high turnover rate. In 
healthy condition the ratio of Aβ40:Aβ42 is 9:1 (Ramona Quelle 35, 36), whereas in malignant situation 
this ratio shifts towards more Aβ42 (Kuperstein et al. 2010). It is known that mutations in the γ-secretase 
or APP (Chartier-Harlin et al. 1991; Goate 2006; Selkoe & Wolfe 2007) lead to the production of more 
toxic Aβ42 and a less efficient or impaired clearance of Aβ42 (Mawuenyega et al. 2010; Saido & Leissring 
2012) contributes to the accumulation of Aβ42 in AD. The increase in Aβ42 levels results in the formation 
of soluble oligomeric accumulations and finally the deposition of amyloid plaques found in the AD brain 
(Bitan et al. 2003; Snyder et al. 1994; Chen & Glabe 2006). The series of events are described in the 
amyloid cascade hypothesis (Figure 1). 
 
 
1.1.2  The amyloid cascade hypothesis  
The widely supported amyloid cascade hypothesis implies the accumulation of Aβ and the resulting 
deposition of senile plaques in the brain parenchyma (John Hardy & Allsop 1991; Hardy & Selkoe 2002) 
as the primary event driving AD pathology, with the hyperphosphorylation of tau and other downstream 
events (e.g. neuroinflammation) as secondary effects, which eventually cause neuronal dysfunction and 
neuronal death (Figure 1). Evidence supporting this hypothesis arises from studies of familiar cases of 
early-onset AD, which is caused by mutations in the genes encoding for APP (APP) and for the catalytic 
centers of the γ-secretase complex, Presenilin (PSEN1) 1 and 2 (PSEN2) (Chartier-Harlin et al. 1991; 
Sherrington et al. 1995; Goate 2006; Selkoe & Wolfe 2007). Mutations in these “deterministic genes” 
were shown to cause Aβ deposition due to increased Aβ42 production and self-aggregation (Levy et al. 
1990; Van Broeckhoven et al. 1990; Hardy & Selkoe 2002). These familial cases of AD apply for 
approximately 1-5% of all AD cases (Blennow et al. 2006). Other findings supporting the amyloid cascade 
hypothesis and supporting Aβ deposition as the initiating step of AD pathology are the following (Hardy 
2002): Tau aggregation alone is not sufficient to induce Aβ plaque formation. Mutations in the gene 
encoding tau are, at worst, causing frontotemporal dementia (FTD) with Parkinsonis (Poorkaj et al. 1998; 
Hutton et al. 1998; Goedert & Spillantini 2000). Furthermore, changes in Aβ metabolism, APP 
processing and initial amyloid plaque formation occur rather before tau alterations than after (Hardy et al. 
1998; Jada Lewis et al. 2001). This was supported by studies with transgenic mice overexpressing both, 
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APP and tau. Compared to transgenic mice overexpressing tau alone, the combination of co-expressing 
mutant human APP and tau showed an increase in tau tangle formation, while the amount of amyloid 
plaques remained the same. In addition, studies have shown that an imbalance in Aβ clearance also 
contributes to the risk of developing late onset AD (Kang et al. 2000; Hardy & Selkoe 2002). However, 
the amyloid cascade hypothesis does not fully explain all the processes occurring in AD pathogenesis and 
therefore is still under debate. The strongest argument that something is missing in this cascade hypothesis 
and is still of need of filling in more details, is the fact that the number of Aβ plaques in the brain do not 
necessarily correlate well with the degree of AD patients symptoms (Perez-Nievas et al. 2013; Sloane et al. 
1997). In fact, it has been shown that not the amount of insoluble Aβ aggregates, but rather the total 
amount of Aβ correlate better with the severity of AD symptoms (Naslund et al. 2000; Haass & Selkoe 
2007), which also include soluble Aβ. Recent evidence demonstrate that soluble oligomeric Aβ play a 
causative role in synaptic dysfunction in AD (Lambert et al. 1998; Walsh et al. 2002) sparking ongoing 
debates whether soluble oligomers or insoluble fibrils are the neurotoxic species. Still, the exact 
mechanisms of how Aβ, in any form whatsoever, causes neurotoxicity is not fully understood and gaps 
need to be filled.  
 
 
 
 
Figure 1: Schematic overview of the amyloid cascade hypothesis. This graph was modified from (Karran et al. 
2011) and shows an overview of the series of events occurring in AD of the strong supported hypothesis that the 
accumulation and aggregation of Aβ is the triggering event leading to neuronal damage and neurotoxicity in AD 
pathology. 
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1.2 Disturbed redox homeostasis in AD 
1.2.1  The free radical  theory of  aging 
It is still uncertain how the neurotoxicity of Aβ is mediated. Oxidative stress has been proposed to be 
involved in this. The overall term ‘oxidative stress’ became increasingly popular and has been used in 
various diseases. There are several hypotheses of how oxidative stress could contribute to neuronal damage 
in AD. Some studies have addressed the role of oxidative stress and inflammation in AD, which includes 
the activation of microglia and a release of numerous inflammatory mediators including pro-inflammatory 
cytokines (Heneka MT, et al., 2014; Block ML et al., 2007; McGeer R et al., 2001). Other studied have 
shown that a knock-down of superoxide dismutase (SOD), a major scavenger of ROS generated in 
mitochondria, leads to an accelerated accumulation of Aβ plaques in an AD mouse model, suggesting that 
disturbance of free radical metabolism contribute to the amyloid pathology characteristic of AD (Li et al., 
2004). This concept of the ‘oxidative stress theory’ is originated from the ‘The free radical theory of 
aging’, which was first introduced in 1956 and a few years later renamed as the ‘mitochondrial free radical 
theory of aging’ by Denham Harman (Harman 1956; HARMAN 1972). This theory suggests the 
accumulation of free radicals, with mitochondria as major source and target of reactive oxygen species 
(ROS), which over time are causing tissue damage and cell death. In order to also include, for example, 
hydrogen peroxide (H2O2), which is an oxygen species but not a radical, the now common concept 
‘oxidative stress theory of aging’ was introduced by Yu and Yang (Yu & Yang 1996). However, this term is 
still evolving. Redox homeostasis is currently the most precise description of the balance between various 
oxidants and antioxidants (Sies 2015). An imbalance on either side is causing a disturbance of the redox 
homeostasis that may cause redox stress such as oxidative stress or reductive stress that have both been 
linked to AD (Gella & Durany 2009; Zhao et al. 2013; Lloret et al. 2016).  
 
1.2.2  Oxidants and antioxidants 
The group of oxidants includes free radicals and ROS that are unstable and very reactive molecules by 
themselves or undergo further reactions to generate free radicals. Among them are “superoxide anion 
radical, hydrogen peroxide, hydroxyl radical, electronically excited states such as singlet molecular oxygen, 
as well as the nitric oxide radical and peroxynitrite” (Sies 2015). Oxidants are constantly produced, for 
example during mitochondrial respiration. A certain amount of oxidants are needed for important 
biological activities such as cell signaling, host defense in phagocytic cells to combat infection and the 
regulation of proliferation upon stimulation by growth factors (Finkel 1998; Finkel & Holbrook 2000; 
Hamanaka & Chandel 2010). For maintaining the balance of redox homeostasis, the antioxidant defense 
system is very important to counterbalance and scavenge the effects of these oxidants. This defense system 
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is composed of enzymatic and non-enzymatic antioxidants (Finkel & Holbrook 2000; Zhao et al. 2013). 
ROS detoxification enzymes include for example superoxide dismutase (SOD), catalase (Cat), glutathione 
reductase (GR), and glutathione peroxidase (GPx) and belong to the enzymatic antioxidants. Vitamin C 
(ascorbic acid), vitamin E (alpha-tocopherol), carotenoids, polyphenolic compunds and glutathione 
belong to the non-enzymatic antioxidants and directly scavenge free radicals (Sies 1997; SIES 1993). As 
mentioned before, an imbalance in oxidants and antioxidants, for example due to low efficiency of the 
antioxidant defense system or an overproduction of ROS, disturbs the redox homeostasis and is linked to 
redox stress that implicated in AD. Constructive criticism was mentioned regarding the very general and 
broad use of the term oxidative stress without identifying the exact species that is affected or disturbed 
(Sies 2015). Identifying the exact specimen involved in the disturbed redox homeostasis will help 
deciphering the exact mechanisms behind pathophysiological processes.  
In this study, I focused on hydrogen peroxide (H2O2), a major ROS, which is a rather stable and non-
radical oxidant. When it is converted into more reactive species it may cause oxidative damage. Moreover, 
H2O2 is also a signaling molecule and involved in the regulation of biological processes such as autophagy, 
proliferation and survival (Gough & Cotter 2011; Veal et al. 2007; Plaine 1955). In context with Aβ, the 
overproduction of H2O2 has been linked to neurotoxicity (Tabner et al. 2005; Behl et al. 1994). 
Additionally, I focused on glutathione, which is a low-molecular weight scavenger and represents a major 
antioxidant in the cell and is known for its protective effects against oxidative damage (Dringen 2000). It 
is a water-soluble, low molecule weight tripeptide, consisting of glutamate, cysteine and glycine. 
Glutathione is a crucial redox regulator and involved in the regulation of various cellular processes 
including gene expression, DNA and protein synthesis, cell proliferation and apoptosis (Aquilano et al. 
2014; Franco & Cidlowski 2009). Glutathione cycles between a reduced (GSH) and oxidized (GSSG) 
state and its ratio (GSH/GSSG) and redox potential (EGSH) have been widely used to evaluate 
perturbations in cellular redox homeostasis (Simone C. Albrecht et al. 2011; Currais & Maher 2013; 
Rebrin et al. 2004). Alterations in glutathione homeostasis are implicated in various human diseases, 
including AD (Mandal et al. 2015). 
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1.2.3  Oxidative stress  in AD 
There is accumulating evidence that oxidative stress is a characteristic of AD brains next to senile plaques 
and NFTs (Zhao et al. 2013). Recent studies demonstrate that AD pathogenesis correlates with increased 
overproduction of ROS and/or a decrease in the anti-oxidative defense system (von Bernhardi & Eugenín 
2012; Cai et al. 2011). Several cellular insults that increase ROS in AD pathogenesis are mitochondrial 
dysfunction (Lin & Beal 2006) and inflammation (Wyss-Coray & Mucke 2002; Liddelow et al. 2017; 
Heneka et al. 2014; Block et al. 2007). So far, it has been reported that elevated levels of oxidative stress 
markers can be found in patients with mild cognitive impairment (MCI), an intermediate stage between 
normal aging and dementia (Yonas E. Geda, MD 2012), and in post mortem AD patients brains (Harris 
et al. 1995; Gella & Durany 2009). These markers that are all associated with AD pathology include 
protein carbonylation, lipid peroxidation such as 4-hydroxy-2,3-nonenal (HNE) and malondialdehyde 
(MDA), advanced glycation endproducts (AEGs) and DNA oxidation such as 8-hydroxy-2-
deoxyguanosine (8OHdG) and 8-hydroxyguanosine (8OHD) (Gella & Durany 2009; Sayre et al. 1997; 
Harris et al. 1995; Sultana, R., Perluigi, M., Allan Butterfield 2013; Butterfield et al. 2001). In addition to 
the observations of various oxidative damage endproducts, alterations in the activity or expression of ROS 
detoxification enzymes, such as superoxide dismutase (SOD) and catalase have been observed in dementia 
and AD patients (Padurariu et al. 2010; Omar et al. 1999; Gsell et al. 1995; Furuta et al. 1995). 
Moreover, a decrease in glutathione concentration during aging (Chen et al. 1989; Gella & Durany 2009) 
and low levels of glutathione are observed in patients with MCI and mild AD (Mandal et al. 2015; Ansari 
& Scheff 2010; Bermejo et al. 2008) that also contribute to the oxidative stress conditions. 
Previous studies have pointed out the connection between oxidative stress and Aβ-mediated toxicity (Zhao 
et al. 2013). It has been shown that dependent on its levels and aggregation state Aβ has a dual role in the 
relationship to oxidative stress (Zou et al. 2002; Plant et al. 2003; Zhao et al. 2013). On the one hand, 
abnormal accumulation and aggregation of Aβ can promote oxidative stress (Mohmmad Abdul et al. 
2006; Matsuoka et al. 2001; Smith et al. 1998) that enhances neuronal oxidative damage (vice versa), 
whereas on the other hand low levels of Aβ (picomolar and low nanomolar) can be beneficial for the 
maintenance of the cellular redox status and can be protective against oxidative stress (Zhao et al. 2013; 
Nunomura et al. 2006). Several in vitro and in vivo studies reveal that Aβ can promote oxidative stress. For 
example, Aβ treatment of clonal CNS cell line B12 (PC12) cells and CNS primary cultures increased 
H2O2 and lipid peroxide levels (Behl et al. 1994) in vitro. Additionally, it has been shown that age-linked 
Aβ accumulation was associated with elevated H2O2, nitric oxide production and oxidative modifications 
of proteins and lipids in AD transgenic mouse models with APP and PS-1 mutations (Smith et al. 1998; 
Matsuoka et al. 2001; Apelt et al. 2004; Mohmmad Abdul et al. 2006), connecting Aβ with the 
promotion of oxidative stress. Conversely, it was also shown that oxidative stress could promote Aβ. In 
AD transgenic mouse models with overexpression of APP mutant (Tg19959 and Tg2576), it has been 
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reported that manipulating the antioxidant defense system by heterozygous knockout of MnSOD (SOD2) 
or deletion of Cu-Zn-SOD (SOD1), increased the amyloid plaque burden, Aβ oligomerization and 
accelerated the loss of spartial learning and memory (Li et al. 2004; Murakami et al. 2011). And on the 
other hand overexpression of SOD2 decreased amyloid plaque burden and protein oxidation in vivo 
(Dumont et al. 2009). Despite all this research, it is still under debate whether oxidative stress is the 
primary cause or a secondary effect of this age-related disease and whether changes in the cellular redox 
balance have a direct impact on the onset and progression of AD. Most importantly, direct in vivo 
evidence showing whether changes in redox balance are directly linked to Aβ neurotoxicity is still missing. 
 
 
1.3 c-Jun N-terminal Kinase (JNK) stress signaling in AD 
Several signaling pathways regulate the cellular response to various stresses and get activated in response to 
oxidative stress. Among these stress-signaling pathways is the c-Jun N-terminal kinase (JNK) pathway. 
JNKs, also known as stress-activated protein kinases (SAPKs), belong to the mitogen-activated protein 
kinase (MAPK) family. The JNK pathway governs a range of biological processes such as brain 
morphogenesis, synaptic plasticity and memory formation and is an important regulator of stress responses 
and apoptosis in AD pathology (Coffey 2014; Liu & Lin 2005; Manning & Davis 2003). Not only ROS, 
but also other stressors including inflammatory cytokines and ultraviolet irradiation can activate the JNK 
stress pathway (Biteau et al. 2011). Additionally, in vitro studies have shown that treatment with Aβ 
peptides induce JNK activation in primary neuronal cultures (Morishima et al. 2001; Yarza et al. 2016). It 
has been reported that JNK activation is linked with Aβ accumulation and cell death (Tare et al. 2011; 
Marques et al. 2003; Jang & Surh 2002; Shoji et al. 2000). Furthermore, a co-localization with Aβ and 
increased expression of phosphorylated JNK (pJNK) has been observed in post-mortem AD patient brains 
(Zhu et al. 2001; Ferrer et al. 2001; Coffey 2014). Other studies have presented beneficial effects of JNK 
signaling. In Drosophila it has been shown that JNK activation acts protective against oxidative stress insult 
due to the transcriptional activation of autophagy (Wu et al. 2009). Also, it has been shown that increased 
JNK signaling extends life span and is important for oxidative stress tolerance (Wang et al. 2003). Thus, it 
is of great importance to investigate how changes in redox homeostasis can be translated into a death 
signal and whether this is promoted via stress-responsive pathways, such as JNK.  
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1.4 Drosophila  as a model organism for AD  
Numerous in vitro and in vivo models have been applied to investigate and understand disease-related 
mechanisms of AD pathology and aiming to find targets for successful therapeutic treatment. Several 
transgenic mouse models have already been established. They range from overexpression of human tau, 
APP, or Presenilin 1 with disease-related mutations, triple transgenic mice models expressing all three 
mutated human genes (J. Lewis et al. 2001; Oddo, Caccamo, Kitazawa, et al. 2003; Oddo, Caccamo, 
Shepherd, et al. 2003; Stover et al. 2015) to injecting Aβ plaques-containing brain homogenates from AD 
patients into the hippocampus of APP mice to induce AD-like pathology (Meyer-Luehmann et al. 2008). 
All these mouse models have provided and will provide valuable insights into various disease-related 
mechanism of AD. However, non-vertebrate models possess great advantages towards mammalian models 
and have shown to be equally useful in contributing and adding knowledge to the broad field of AD 
research. The most obvious advantage of using Drosophila models is the easy handling in addition to their 
time and cost-efficiency compared to mammalian models. The wide availability of genetic tools and the 
large number of publicly available transgenic stocks Drosophila represent an advantageous model organism 
(Chan & Bonini 2000; Dietzl et al. 2007; del Valle Rodríguez et al. 2011; Venken et al. 2011). Thus, 
Drosophila models provide a favored platform for large-scale screening approaches (Shulman & Feany 
2003; Greene et al. 2005; Cao et al. 2008; Rival et al. 2009).  
In addition, the various cellular and genetic similarities with humans including 75% of all signaling 
pathways being conserved and 65% of human-disease-associated genes having a Drosophila homolog, 
Drosophila has proven to be a suitable model organism for diverse diseases (Bellen et al. 2010). 
Particularly, the “complex” neuronal system of the fly has been used to study neuronal dysfunction and 
neurodegenerative diseases (McGurk et al. 2015; Sang & Jackson 2005). Drosophila lacks the β-secretase 
activity and does not posses APP (McGurk et al. 2015). However, Drosophila has all homologs of all 
components of the γ-secretase complex and an APP homolog, which is called APP-like (APPL) (Boulianne 
et al. 1997; Hong & Koo 1997; Rosen et al. 1989). To mimic neurodegeneration and generate 
histopathological hallmarks of AD in Drosophila different approaches can be used. On the one hand fly 
mutants of homologs of disease-associated genes can be studied (Lessing & Bonini 2009) and on the other 
hand human transgenes, such as APP, β-secretase or different variants of Aβ can be overexpressed in 
specifically defined tissues to mimic pathological hallmarks of AD and investigate neurotoxic effects 
(Finelli et al. 2004; Iijima et al. 2004). In this study, I used an Aβ aggregation model, which is based on 
the expression of the coding sequence of different variants of the human Aβ peptide that are fused to an 
extracellular secretion signal (Iijima et al. 2004; Crowther et al. 2005; Sowade & Jahn n.d.). 
From the identification of the white gene by Thomas H. Morgan in 1910 until now the applications and 
genetic tools for using Drosophila as model organism have continuously be evolved (Morgan 1910; Bellen 
et al. 2010). Favorable methods that I used in the present work were the cell-specific single and dual 
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expression systems Gal4/UAS (upstream activating sequence) and/or LexA/lexAop (Brand & Dormand 
1995; Lai & Lee 2006) to co-express different Aβ variants and/or different redox sensors in different cell 
types. To monitor the cell stress response in the fly brain I validated specific redox sensors (Simone C. 
Albrecht et al. 2011) and JNK (Chatterjee & Bohmann 2012) reporters that are explained in more detail 
in each corresponding results part.  
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2.  Objectives 
Recent clinical trials, targeting Aβ initially have been promising to stop and slow down Aβ production 
(Kennedy et al. 2016), but ultimately failed or were discontinued due to lack of efficacy (Morris et al. 
2014). Previous studies have shown that the amount of Aβ plaques does not correlate with the severity of 
AD symptoms (Perez-Nievas et al. 2013; Chételat et al. 2010; Sloane et al. 1997), which strongly indicates 
the importance and urgency to investigate other mechanisms that are involved in the early stages of AD 
progression to find new targets for this still incurable disease. There is growing evidence that AD 
pathogenesis correlates with increased oxidative stress due to an imbalance in redox homeostasis, either 
due to overproduction of reactive oxygen species (ROS) and/or a decrease in the anti-oxidative defense 
system (von Bernhardi & Eugenín 2012; Cai et al. 2011). Several cellular insults elevating oxidative stress 
have been proposed in AD, such as mitochondrial dysfunction (Lin & Beal 2006) and inflammation 
(Liddelow et al. 2017; Heneka et al. 2014; Block et al. 2007). However, it is still under discussion whether 
an imbalance in redox homeostasis has a causative role in AD or is a consequence of neuronal 
degeneration. It is still to resolve in which scale changes in redox balance impact the onset and progression 
of AD.  
Importantly, providing direct in vivo evidence for the connection of redox imbalance with Aβ 
neurotoxicity is of high importance. The present study aimed to provide new insights into a 
understanding of the impact of changes in redox homeostasis and the involvement of stress responsive 
pathways in the onset and progression of AD. The overall aim was to analyze potential connections 
between changes in the cellular redox homeostasis on the onset of Aβ-induced neurotoxicity. In addition, I 
was also interested in how redox changes can be translated into a death signal. The involvement of the 
JNK pathway as an important regulator of stress responses and apoptosis in AD pathology has been 
previously reported (Coffey 2014; Liu & Lin 2005; Manning & Davis 2003). Moreover, shedding light 
on the ongoing debate whether JNK activation contributes to cell death in response to oxidative stress 
(Sclip et al. 2014; Tare et al. 2011; Marques et al. 2003; Jang & Surh 2002; Shoji et al. 2000) or acts as a 
protection against it (Liu et al. 2015; Wu et al. 2009; Wang et al. 2003) is of high importance. 
Furthermore, the neuron-glia interactions represent an important and critical aspect in the development of 
AD pathogenesis and are so far not fully understood. The role of glia cells in AD have been previously 
described in the context of inflammatory processes, in which Aβ can lead to activated microglia, which in 
result secret ROS and inflammatory cytokines, contributing to this vicious circle which contribute to 
neuronal damage (Liddelow et al. 2017; Heneka et al. 2014; Block et al. 2007). But it is still not well 
characterized which mechanisms mediate the crosstalk between neurons and glia cells and whether changes 
in redox balance play a crucial role in this. Therefore, in this study, I aimed to specifically monitor 
neuronal and glial alterations in redox state in an entire organ, the Drosophila brain, to explore the role of 
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neuron-glia communication in this context and associate it directly with changes in neurotoxicity using 
longevity assays. In this context, the development of qualified tools to analyze the role of redox changes, at 
early stages, and in more detail is very important.  
In this study, I present an in vivo model, combining quantitative redox analysis with an in vivo Drosophila 
model of Amyloid-beta (Aβ) aggregation. The major novelty and advance of this system is the 
combination of two powerful tools: 1) the establishment of dual expression Drosophila models allowing 
the pan-neuronal expression of different Aβ variants (non-toxic/toxic) with the independent expression of 
the redox sensors in neurons or glia cells and 2) the use of genetically encoded fluorescence-labeled redox 
sensors (roGFP2s) allowing the quantitative real-time measurement of redox changes in different cellular 
compartments (cytoplasm or mitochondria), allowing the discrimination of the glutathione redox 
potential or H2O2 levels, respectively (Barata & Dick 2013; Gutscher et al. 2013; Simone C. Albrecht et 
al. 2011). The aim was to examine early events of neuronal dysregulation and disease onset in vivo and 
further provide a screening platform for possible disease modifying therapies.  
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3.  Materials  and Methods 
3.1 Materials 
3.1.1  Antibodies ,  Chemicals ,  Reagents   
Table 1: List of Antibodies 
Name Dilution Source Identifier 
6E10 for total Aβ detection  1:500 or 
1:1000 
Covance  Sig-39320-200  
Lot: D11LF02498 
Actin 1:500 Sigma-Aldrich A2228 
Goat anti-Mouse IgG (H+L), Alexa Fluor® 568 1:2500 Thermo Fisher 
Scientific 
A11004  
Goat α-mouse IgG-HRP 1:2000 Thermo Fischer 
Scientific 
62-6520; RRID: 
AB_88369 
 
 
Table 2: List of chemicals and reagents 
Name Source Identifier 
Agar (for standard fly food) Biomol A090#4 
Agar (for holidic fly food) Difco 214530 
β-mercaptoethanol  Sigma-Aldrich M6250-250mL 
BD DifcoTM Granulated Agar  Fisher Scientific  10006334 
Biotin Sigma Aldrich B4501 
Bovine Serum Albumin (BSA) Sigma-Aldrich A2153-100G 
Brilliant blue Carl-Roth 3862.1 
Calcium chloride Sigma-Aldrich C7902 
Ca pantothenate  Sigma Aldrich P2250 
Cholesterol Sigma Aldrich C8667 
Choline chloride Sigma Aldrich C1879 
ColorPlus™ Prestained Protein Ladder, Broad 
Range 
New England Biolabs 
(NEB) 
P7711 S 
CompleteTM Protease Inhibitor Cocktail Tablets  Santa Cruz Biotechnology  sc-29130 
CuSO4.5H2O Sigma Aldrich C7631 
Corn flour Bäko Süd-West eG 11474 
Desoxyribunucleoside triphosphate (dNTPs) mix Carl Roth R0182 
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Dimethyl sulfoxide (DMSO) Sigma-Aldrich D8418-100ML 
Dream Taq DNA polymerase (5 U/µl) Thermo Fisher Scientific EP0701 
EDTA-Free Protease Inhibitor mix Sigma-Aldrich COEDTAF-RO 
11873580001 
Ethanol  Sigma-Aldrich  12694 
Ethylenediaminetetraacetic acid (EDTA)  Carl Roth  X986.2 
Express Five SFM Medium Life Technologies 10486025 
Fetal bovine serum (FBS) Superior Biochrom  S-0615 
FeSO4.7H2O Sigma Aldrich F7002 
Formaldehyde, 37%  Sigma-Aldrich  252549-25ML 
GenLadder 100 bp  GENAXXON bioscience M3094.0050 
GenLadder 250bp -10kb GENAXXON bioscience M3328.0050 
Glacial acetic acid Fisher Scientific A/0400/PB15 
Glucose Sigma-Aldrich G7021 
Glycerol  Carl Roth 7530.1 
Glycine  Sigma Aldrich G7126 
Guanidine hydrochloride  Carl Roth  6069.2 
HDGreenTM DNA Stain  Intas Science Imaging 15115390 
Hoechst 33342 Thermo Fisher Scientific 631311 
Inosine Sigma Aldrich I4125 
Isopropanol  Sigma-Aldrich 33539-2.5L 
KH2PO4 Sigma Aldrich P9791 
L-alanine Sigma Aldrich A7627 
L-arginine Sigma Aldrich A5131 
L-asparagine Sigma Aldrich A0884 
L-aspartic acid Sigma Aldrich A6683 
L-cysteine (HCl) Sigma Aldrich C1276 
L-glutamine Sigma Aldrich G3126 
L-histidine Sigma Aldrich H8000 
L-isoleucine Sigma Aldrich I2752 
L-leucine Sigma Aldrich L8912 
L-lysine (HCl) Sigma Aldrich L5626 
L-methionine Sigma Aldrich M9625 
L-phenylalanine Sigma Aldrich P2126 
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L-proline Sigma Aldrich P0380 
L-serine  Sigma Aldrich S4500 
L-threonine  Sigma Aldrich T8625 
L-tryptophan Sigma Aldrich T0254 
L-tyrosine Sigma Aldrich T3754 
L-valine Sigma Aldrich V0500 
Magnesium chloride hexahydrate  Carl Roth   A537.4 
Malt extract  BakeMark Germany 728985 
MgSO4 (anhydrous) Sigma Aldrich M7506 
MnCl2.4H2O Sigma Aldrich M3634 
Myo-inositol Sigma Aldrich I7508 
Nicotinic acid Sigma Aldrich N4126 
Nipagin (Methyl-4-Hydroxybenzoat) VWR International 1.06757.5000 
Nonfat dried milk powder Panreac AppliChem  A0830.1000 
PeqGOLD Universal Agarose  Peqlab Biotechnology 
GmbH  
732-2790 
Phosphate-buffered saline (PBS) tablets  Panreac AppliChem  A9191.0100 
Phosphoric acid Sigma-Adrich N/A 
PhosSTOP Phosphatase Inhibitor mix Sigma-Aldrich PHOSS-RO 
Propionic acid (for standard fly food) VWR International 8.00605.2500 
Propionic acid (for holidic fly food) Sigma Aldrich P5561 
Proteinase K Panreac AppliChem 
GmbH 
A4392 
Pyridoxine (HCl)  Sigma Aldrich P9755 
Quick Start Bradford 1x Dye Reagent Bio-Rad 5000205 
Riboflavin Sigma Aldrich R4500 
Sarkosyl/N-Lauroylsarcosine sodium Sigma-Aldrich  137-16-16 
Sodium chloride Sigma-Aldrich  31434-1KG-R 
Sodium dodecyl sulfate (SDS) pellets  Carl Roth  CN30.1 
Sodium folate Sigma Aldrich F7876 
Sodium fluoride  Panreac AppliChem  A3904.0025  
Sodium glutamate Sigma Aldrich G5889 
Sodium hydrogen carbonate  Sigma-Adrich S5761 
Sodium orthovanadate  Sigma-Aldrich  S6508 
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Sodium phosphate monobasic monohydrate Sigma-Aldrich S9638 
Soybean meal  Amorebio GmbH 895 
SpectraTM Multicolor Low Range Protein Ladder  Thermo Fisher Scientific  26628 
Sugar beet syrup Grafschafter Krautfabrik 01901 
Sucrose Sigma Aldrich S1888 
SuperSignal West Pico Chemiluminescent 
Substrate 
Thermo Fisher Scientific 34080 
 
SuperSignal West Femto Chemiluminescent 
Substrate 
Thermo Fisher Scientific 34095 
Thiamine (aneurin) Sigma Aldrich T4625 
Thioflavin S Sigma-Aldrich T1892 
Trizma® base  Sigma-Aldrich  T1503-1KG 
Trizma® hydrochloride Sigma-Aldrich T3038 
Triton X-100  Sigma-Aldrich  T8787  
Tween-20 Sigma-Aldrich P1379-1L 
Uridine Sigma Aldrich U3750 
VECTASHIELD® Mounting Medium  Vector Laboratories  VEC-H-1000 
Yeast Heierler Cenovis GmbH 98206 
ZnSO4.7H2O Sigma Aldrich Z0251 
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3.1.2  Buffers  
Table 3: List of buffers 
Name Components 
AlphaLISA buffer I  
(4 M Guanidine buffer) 
50 mM Trizma base  
1x protease inhibitor  
1 mM EDTA  
4 M guanidine hydrochloride  
pH 7.4  
(stored at 4 °C, shortly before use at RT)  
AlphaLISA buffer II 
(400 mM Guanidine buffer) 
50 mM Trizma base  
1x protease inhibitor  
1 mM EDTA  
400 mM guanidine hydrochloride  
pH 7.4  
(stored at 4 °C, shortly before use at RT) 
AlphaLISA buffer III 
(without Guanidine) 
50 mM Trizma base  
1x protease inhibitor  
1 mM EDTA  
pH 7.4  
(stored at 4 °C, shortly before use at RT) 
Genomic DNA extraction buffer 10 mM Trizma hydrochloride (pH 8.0) 
1 mM EDTA  
25 mM sodium chloride  
1 % (v/v) proteinase K (200 µg/ml) 
Aliquoted and stored at -20°C (without 
Proteinase K). Proteinase K was always added 
freshly directly before use. 
Lämmli 60mM Trizma base (pH 6.8)  
2 % (w/v) SDS 
10% glycerol 
 5 % (v/v) β-mercaptoethanol  
0.01 % (w/v) brilliant blue  
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Protein extraction buffer 50 mM Trizma base (pH 7.5) 
2 mM sodium orthovanadate 
50 mM sodium fluoride  
50 mM β-Glycerophosphate disodium salt 
hydrate  
1 x phosphatase inhibitor  
1 x protease inhibitor  
150 mM sodium chloride  
2 mM magnesium chloride  
1 % (w/v) N-Lauroylsarcosine  
1 % (v/v) Triton X-100  
1 % (w/v) SDS  
NuPAGE MES SDS Running Buffer Composition see specifications from Life 
Technologies 
Rinaldini solution (for live-imaging)  
(Harzer et al. 2013) 
8mg/ml NaCl 
0.2mg/ml KCl 
0.05mg/ml NaH2PO4 
1mg/ml NaHCO3 
1mg/ml Glucose  
Rotiphorese® NF 10x TBE-Buffer (0.5x) Composition see specifications from Carl Roth 
GmbH 
 
 
3.1.3  Consumables,  Equipment and Kits 
Table 4: List of consumables 
Name Source 
AmershamTM ProtranTM 0.1 µm nitrocellulose blotting membrane GE Healthcare 
Centrifuge tubes (Polypropylen tubes 15 ml and 50 ml) Greiner Bio-One  
Corning® 96-well microplates (Product #3642)  Corning  
Corning® Costar® Stripette® serological pipettes (5 ml, 10 ml and 25 ml)  Sigma-Aldrich  
Eppendorf Safe-Lock tubes (1.5 ml)  Eppendorf  
Forceps, Dumont No. 5  neoLab  
Hard-Shell® 96-well PCR Plate (Product #HSP9601)  Bio-Rad  
Microscope slides  Thermo Fisher Scientific  
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Microseal® B Adhesive Sealer  Bio-Rad  
NuPAGETM NovexTM 4-12 % Bis-Tris gels Thermo Fischer Scientific 
PCR tubes (0.2 ml, RNase-free)  nerbe plus  
Pipette tips (200 µl, 1000µl) Greiner Bio-One 
Pipette tips TipOne® (10 µl)  STARLAB Group  
Precellys mashing tubes (CK14 – 0.5 ml)  Bertin Instruments  
Premium surface pipet tips (100 µl, 1250 µl)  nerbe plus  
RNase-free microfuge tubes (0.5 and 1.5 ml) Thermo Fisher Scientific  
Siliconized microcentrifuge tubes (1.5 ml) Sigma-Aldrich 
 
 
Table 5: List of equipment  
Name Source 
8-well Chambered Coverglass System (NuncTM Lab-TekTM) Thermo Fischer Scientific 
#155411 
24-well plates, 662160 Greiner Bio-One #2511 
AccuBlockTM Digital Dry Bath  Labnet International  
Benchtop Flowbuddy with a blowgun  Genesee Scientific  
C-Digit® Blot Scanner Li-COR® 
Centrifuge 5430 R  Eppendorf  
E-BOX VX2 gel analysis chamber  Vilber Lourmat  
Eppendorf Research® plus pipettes  Eppendorf  
FLUOstar Omega microplate reader  BMG LABTECH  
Laser Scanning Microscope (LSM) 780 and 880 with Airyscan Zeiss  
Leica SP5 Leica Microsystems 
Minilys personal homogenizer  Bertin Corp.  
MiniSpin® table centrifuge  Eppendorf  
Mini-Sub® Cell GT Systems  Bio-Rad 
NanoDropTM Lite Spectrophotometer  Thermo Fisher Scientific  
PIPETBOY acu 2 pipet aid  INTEGRA Biosciences  
PowerPacTM Basic Power Supply  Bio-Rad  
Reax top test tube shaker  Heidolph Instruments  
Rotamax 120 orbital platform shaker  Heidolph Instruments  
RUMED® fly incubator 3201  Rubarth Apparate GmbH 
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Sonorex RK 102 Transistor  BANDELIN  
Stemi 2000 stereomicroscope  Zeiss  
T100 Thermal Cycler for PCR  Bio-Rad 
ThermoCell Mixing Block MB-102  Bioer  
Trans-Blot® TurboTM Transfer  System Bio-Rad 
Ultimate Flypad  Genesee Scientific  
Wide Mini-Sub® Cell GT Horizontal Electrophoresis System  Bio-Rad  
XCell SureLocTM Mini-Cell Electrophoresis System Invitrogen 
 
 
Table 6: List of Kits   
Name Source Identifier 
Amyloid β 1-x (human) AlphaLISA Detection Kit  PerkinElmer AL288C 
Effectene Transfection Reagent Kit Qiagen 301427 
DCTM Protein assay (Lowry)  Bio-Rad 500-0113 
Trans-Blot® TurboTM RTA Transfer Kit  Bio-Rad 1704270 
 
 
3.1.4  Drugs and Antioxidants  
Table 7: List of Antioxidants and Drugs for feeding experiments 
Name End concentration for 
feeding experiment 
Source Identifier 
Ascorbat (L-ascorbic acid)  0.36mM Sigma Aldrich A0278-25G 
α-tocopherol (Vitamin E, Trolox) 1.1mM 
6.7mM 
13.3mM 
Sigma Aldrich T3251-5G 
Buthionine Sulfoximine (BSO) 1mM Cayman Chemical 
Company 
Cay14484-1 
Buthionine Sulfoximine (BSO) 1mM Sigma Aldrich B2515-500MG 
DMSO control 0.2% v/v Sigma Aldrich D8418-100ML 
Ethanol controls 0.75% v/v 
0.026% v/v 
0.7% v/v 
2% v/v 
Sigma Aldrich 12694 
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Hydrogen peroxide, 30% (H2O2) 88mM Carl Roth 8070.2 
NAC (N-acetyl-L-cysteine) 10mg/ml Sigma Aldrich A7250-25G 
NDGA (Nordihydroguaiaretic 
acid) 
16.536mM Sigma Aldrich 74540-1G 
Paraquat dichlorid hydrat pestanal 
(Paraquat) 1mM Sigma Aldrich 36541-100MG 
Propyl gallate 0.1mM Sigma Aldrich 48710-100G-F 
Reduced GSH 0.22mM Sigma Aldrich G4251-5G 
Rotenone 100µM Sigma Aldrich R8875-1G 
Stearic acid (C18) 10% w/v 
 
Santa Cruz 
Biotechnology 
sc-484614A 
 
TCA (L-4-Thiazolidinecarboxylic 
acid) 
0.5% w/v Sigma Aldrich T27502-10G 
tert-Butylhydroquinone (tBHQ, 
Nrf2 inducer) 
0.1% w/v 
0.15% w/v 
Sigma Aldrich 112941-100G 
 
 
3.1.5  Fly l ines 
Table 8: List of Drosophila melanogaster lines 
Name Source or FlyBase Genotype Identifier, BDSC1or 
VDRC2 number 
Driver lines: 
elav-Gal4 P{GawB}elavC155 458 
nSyb-Gal4::nSyb-LexA w*;+;nSyb-Gal4::nSyb-LexA  T.R. Jahn Lab 
repo-Gal4 repo-Gal4;+;+  M. Freeman lab 
(Sepp et al. 2001) 
w*;+;repo-Gal4::nSyb-LexA w*;+;repo-Gal4::nSyb-LexA  T.R. Jahn 
Target lines: 
lexA.op-TAβ40 w*;+;lexA.op-TAβ40 T.R. Jahn 
lexA.op-Aβ42 w*;+;lexA.op-Aβ42 T.R. Jahn 
UAS-Aβ42 w*;pJFRC7-Aβ42;+ (attP40) T.R. Jahn  
                                                      
 
1 Bloomington Drosophila Stock Center (BDSC) 
2 Vienna Drosophila Resource Center (VDRC) 
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cyto-Grx1-roGFP2 w*;pUAST-cyto-Grx1-roGFP2;+ T. P. Dick Lab 
(Simone C Albrecht 
et al. 2011) 
mito-Grx1-roGFP2 w*;pUAST-mito-roGFP2-Grx1;+ T. P. Dick Lab 
(Simone C Albrecht 
et al. 2011) 
cyto-roGFP2-Orp1 w*;pUAST-cyto-roGFP2-Orp1;+ T. P. Dick Lab 
(Simone C Albrecht 
et al. 2011) 
mito-roGFP2-Orp1 w*;pUAST-mito-roGFP2-Orp1;+ T. P. Dick Lab 
(Simone C Albrecht 
et al. 2011) 
Others: 
w1118 w1118;+;+ BDSC 5905 
TRE-DsRed w;TRE-DsRed-2R; + D. Bohman Lab  
(Chatterjee & 
Bohmann 2012) 
 
 
Table 9: List of Drosophila melanogaster lines for genetic screening (ordered from BDSC or VDRC) 
Name Source or FlyBase Genotype Identifier, BDSC or 
VDRC number 
Overexpression lines  
cat-OE w3; P{UAS-Cat.A}2 24621 
dPRX5-OE_1 UAS-dPRX5_2nd W.C. Orr Lab  
dPRX5-OE_2 UAS-dPRX5_3rd W.C. Orr Lab  
Eaat1-OE_WT y1 w1118; P{UAS-Eaat1.Exel}3/TM6B, Tb1 8202 
G6PD5c-OE_1 UAS-G6PD5c_2nd W.C. Orr Lab  
G6PD5c-OE_2 UAS-G6PD5c_3rd W.C. Orr Lab  
Gclc-OE w; pP[UAST]-Gclc6; + W.C. Orr Lab  
GSTsI4-OE UAS-GSTsI4_3rd A.J. Whitworth lab 
Prx4-OE w1118; PBac{WH}Jafrac2f01922 18489 
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SOD1-OE_1 w1; P{UAS-Sod1.A}B36 24754 
SOD1-OE_2 w1; P{UAS-Sod1.A}B37 24750 
SOD2-OE w1; P{UAS-Sod2.M}UM83 24494 
Downregulation lines 
Cat_TRiP_1 y1 sc* v1; P{TRiP.GL01541}attP40 43197 
Cat_TRiP_2 y1 v1; P{TRiP.JF02173}attP2 31894 
cnc_TRiP_1 y1 v1; P{TRiP.JF02006}attP2 25984 
cnc_TRiP_2 y1 v1; P{TRiP.HMS02021}attP40 40854 
dhd_TRiP y1 v1; P{TRiP.GL01285}attP2 41857 
Eaat1_TRiP y1 sc* v1; P{TRiP.HMS02659}attP40/CyO 43287 
Eaat2_TRiP y1 v1; P{TRiP.HMS01998}attP40/CyO 40832 
GclcRNAi P{KK101607}VIE-260B M. Boutros Lab 
VDRC v108022 
GstD1_TRiP y1 sc* v1; P{TRiP.GL01039}attP2/TM3, Sb1 36818 
Keap1_TRiP y1 v1; P{TRiP.HMJ21798}attP40 57801 
MafS_TRiP_1 y1 v1; P{TRiP.HMS02020}attP40 40853 
MafS_TRiP_2 y1 v1; P{TRiP.JF02008}attP2 25986 
PHGPx_TRiP y1 sc* v1; P{TRiP.GL01312}attP40 41879 
SOD1_RNAi_1 w*; P{UAS-Sod1.IR}F103/SM5 24493 
SOD1_RNAi_2 w*; P{UAS-Sod1.IR}4 24491 
SOD2_dsRNA w1; P{UAS-Sod2.dsRNA.K}15/SM5 24489 
TrxR_TRip_1 y1 sc* v1; P{TRiP.GL01017}attP40 36805 
Trxr-1_TRiP_2 y1 v1; P{TRiP.HMJ21198}attP40 53883 
Trxr-1_TRiP_3 y1 sc* v1; P{TRiP.HMS00784}attP2/TM3, Sb1 32984 
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3.1.6  Holidic f ly  food 
Table 10: Protocol for preparing holidic fly food (Piper et al. 2014) 
Ingredients Ingredients Stock solution Amount [Per liter] 
Step 1: Prepare solution with following ingredients:  
Gelling agent Agar  20g 
Base  
 
10x Buffer Glacial acetic acid (30ml/l) 100ml 
  
  KH2PO4 (30 g/l)   
  NaHCO3 (10 g/l)   
Sugar Sucrose  17.12g 
Amino acids L-isoleucine   1.82g 
 L-leucine   1.21g 
 L-tyrosine   0.42g 
Metal ions CaCl2.6H2O 1000x: 250 g/l  1 ml  
 CuSO4.5H2O 1000x: 2.5 g/l  1 ml  
 FeSO4.7H2O 1000x: 25 g/l  1 ml  
 MgSO4 (anhydrous) 1000x: 250 g/l  1 ml  
 MnCl2.4H2O 1000x: 1 g/l  1 ml  
 ZnSO4.7H2O 1000x: 25 g/l  1 ml  
Cholesterol Cholesterol in EtOH (20 mg/ml) 5ml 
Water Water  add to 1l 
Step 2: Autoclave for 15min at 120°C and cool down to 65°C on a stirrer and add the following: 
Amino acids Essential Stock L-arginine  (8 g/l) 60.51ml 
  L-histidine  (10 g/l)  
  L-lysine(HCl)  (19 g/l)  
  L-methionine  (8 g/l)  
  L-phenylalanine (13 g/l)   
  L-threonine  (20 g/l)  
  L-tryptophan  (5 g/l)  
  L-valine  (28 g/l)  
 Non-essential Stock L-alanine (35 g/l)  60.51ml 
  L-asparagine (17 g/l)   
  L-aspartic acid (17 g/l)   
  L-cysteine HCl  (1 g/l)  
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  L-glutamine (25 g/l)   
  glycine  (32 g/l)  
  L-proline (15 g/l)   
  L-serine  (19 g/l)  
 Sodium glutamate 100 g/l 15.13ml 
Vitamins Vitamin Stock (125x) Thiamine (aneurin) (0.1 g/l) 14ml 
  Tiboflavin (0.05 g/l)   
  Nicotinic acid  (0.6 g/l)  
  Ca pantothenate  (0.775 g/l)  
  Pyridoxine (HCl)  (0.125 g/l)  
  Biotin  (0.01 g/l)  
 Sodium Folate (1000x) 0.5 g/l  1ml 
Other 
nutrients 
Stock solution (125x) Choline  chloride (6.25 g/l) 8ml 
  Myo-inositol ( 0.63 g/l)   
  Inosine (8.13 g/l)  
  Uridine (7.5 g/l)  
Preservatives Propionic acid  6ml 
 Nipagin Methyl 4-hydroxybenzoate in 
 95% EtOH (100 g/l)  
15 ml 
 
Step 3: Keep warm at 65°C in water bath and decant it in small 50ml vials. 
All Stock solutions were steril filtered through a 0.22µl filter. CuSO4.5H2O, HeSO4.7H2O, 
Vitamin solution (125x) and Folic acid (0.5g/l) were stored at -20°C and the other stock solutions 
were stored at -4°C. 
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3.1.7  Primers and DNA sequences 
Table 11: List of primers and DNA sequences 
Primer used for genotyping flies 
Target Sequence of forward and reverse primers  
(5`-3`)  
Annealing 
temperature  
Gal4  Forward: GATGCCGTCACAGATAGAT  
Reverse: TTTAAAGCCAATAGATCGA  
52 °C  
 
LexA  
 
Forward: CCTGCCACTGGTGGGACGCG  
Reverse: CGGCGAGGAGGTCACCATCC  
70 °C  
 
lexAop  
 
Forward: CATCCATACAGTAAGCGGAG  
Reverse: ACAGAAGTAAGGTTCCTTCA  
55 °C  
 
UAS-transgene  
 
Forward: TACTGTCCTCCGAGCGGAG 
or CTGCAACTACTGAAATCTGCC 
Reverse: GGCATTCCACCACTGCTC  
59 °C  
 
TRE-DsRed.T4 Forward: 
GATTTCTTATGAGTCATCGTGATTTC 
or: GAGCGCCGGAGTATAAATAGAG 
Reverse: GATACATTGATGAGTTTGGACAAACC 
52°C  
DNA sequences Dr. R.F. Sowade cloned in the pJFRC7 or pJFRC19 vectors  
Name Sequence (5`- 3`)  
TAβ40 
 
GATGCGGAATTTCGCCATGACAGCGGCTACGAAGTGCATCATC
AAAAATTGGTGTTTTTTGCGGAAGACGTGGGCTCGAACAAAGG
CGCGATTATTGGCTTGATGGTGGGCGGCgtggtgggcggcggcggcagcggc
ggcggcggcagcggcggcGATGCGGAATTTCGCCATGACAGCGGCTACGA
AGTGCATCATCAAAAATTGGTGTTTTTTGCGGAAGACGTGGGC
TCGAACAAAGGCGCGATTATTGGCTTGATGGTGGGCGGCGTG
GTGTAA 
Aβ42 GATGCGGAATTTCGCCATGACAGCGGCTACGAAGTGCATCATC
AAAAATTGGTGTTTTTTGCGGAAGACGTGGGCTCGAACAAAGG
CGCGATTATTGGCTTGATGGTGGGCGGCGTGGTGATTGCGTA
A 
Signal Peptide ATGGCGAGCAAAGTCTCGATCCTTCTCCTGCTAACCGTCCATC
TTCTGGCTGCTCAGACCTTCGCCCAG  
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3.1.8  Softwares 
Table 12: List of softwares 
Name Source Identifier 
MS Office  Microsoft Cooperation 2011 
Adobe Illustrator CS6 Adobe Systems Version 16.0.0 
GraphPad Prism  GraphPad Software Inc. Version 7.0a  
Fiji (ImageJ)  NIH, Schindelin et al., 
2012 
Version 2.0.0-rc-
49/1.51a 
Image Studio Lite  LI-COR Biosciences Version 5.2.5 
 
 
3.2 Methods 
3.2.1  Transgenic Drosophila  melanogaster  l ines 
All used Aβ fly lines were generated in our laboratory. To allow the secretion of Aβ by neurons upon pan-
neuronal expression, the human sequences of Aβ42 and TandemAβ40 were cloned downstream of a 
secretory signal peptide (Crowther et al. 2005). I used Aβ42 as the neurotoxic variant and TandemAβ40, a 
dimer of two Aβ40 monomers linked via a twelve amino acid linker (Speretta et al. 2012), served as a 
negative control for non-toxic cellular effects based on protein accumulation. In most experiments, Aβ was 
expressed under the control of the LexA/LexAop expression system. In the experiments shown in Figure 4 
C, D, F and G, I used the Gal4/UAS expression system with the pJFRC7 vector (Addgene #26224, 
(Pfeiffer et al. 2010)) for pan-neuronal Aβ expression. The pJFRC19 vector (Addgene #26224) was used 
for both w; +; lexA.op-Aβ42 and w; +; lexA.op-TAβ40 (Pfeiffer et al. 2010). Transgenic flies were generated 
by phiC31 integrase-mediated transgenesis (Bischof et al. 2007) using attP landing sites 25C7 (attP40 for 
2nd chromosome) and 68A4 (attP2 for 3rd chromosome). The PD Dr. T.P. Dick laboratory provided all 
used redox sensor flies (pUAST-cytoGrx1-roGFP2, pUAST-cyto-roGFP2-Orp1, pUAST-mito-roGFP2-
Orp1) (Simone C. Albrecht et al. 2011). Prof. Dr. W.C. Orr (Southern Methodist University, Dallas, 
USA) kindly provided the UAS-Gclc-OE fly line (w; pP[UAST]-Gclc6; +) as published in (Orr et al. 
2005). The Gclc-RNAi fly line (VDRC v108022) was obtained from the Prof. Dr. Michael Boutros 
laboratory (DKFZ Heidelberg, Germany). The JNK reporter flies (w; TRE-DsRed-2R; +) were kindly 
given by the Dr. D. Bohmann laboratory (University of Rochester Medical Center, USA), as published in 
(Chatterjee & Bohmann 2012). The Dr. M. Freeman laboratory (University of British Columbia, 
Canada) provided the repo-Gal4 driver line (Sepp et al. 2001) for pan-glial expression. For expression of 
Aβ in all neurons I used the nSyb-LexA, nSyb-Gal4 or the elav-Gal4 driver line, which was acquired from 
the Bloomington Drosophila Stock Center. An overview of all fly lines with their genotype and exact 
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sources can be found in Table 8 and Table 9.  
 
 
3.2.2  Fly Husbandry and feeding experiments 
All fly stocks were kept at 25°C on a 12h light / 12h dark cycle at 60% relative humidity and were raised 
on standard Drosophila food, containing 0,8% (w/v) agar (Biomol), 8% (w/v) corn flour (Bäko Süd-West 
eG), 8% (v/v) malt extract (BakeMark), 0,24% (w/v) nipagin (VWR International), 0,0625% (v/v) 
phosphoric acid (Sigma-Adrich), 0,625% (v/v) propionic acid (VWR International), 1% (w/v) soybean 
meal (Amorebio GmbH), 1,8% (w/v) 2,2% (v/v) sugar beet syrup (Grafschafter Krautfabrik), yeast 
(Heierler GmbH) and water. The composition of the holidic fly food for drug and antioxidant feeding 
experiments are shown in Table 10. All Crosses were reared in 200ml bottles. For all experiments the 
crosses were incubated at 25°C for 3 days and then kept at 29°C during aging before freezing at -80°C at 
the stated time points or for aging. Enclosing adult flies were collected within a 12h time period and were 
mated for 24h. In all experiments only female flies were used. For drug and antioxidant feeding 
experiments, the components were solubilized as required either in water, DMSO or EtOH and added to 
the according fly food. All final concentrations can be taken from Table 7. For the feeding experiments, 
during development the larvae were first maintained on standard Drosophila food. After hatching and 
mating for 24h the flies were transferred to the drug food, which was prepared in standard Drosophila or 
holidic fly food.  
 
 
3.2.3  Preparing of drug and antioxidant f ly  food  
Stock solutions for each compound were prepared freshly before use, subsequently mixed with the 
respective drug or antioxidant (Table 7) and added to the standard Drosophila (see 3.2.2) or holidic fly 
food Table 10, (Piper et al. 2014). Then the drug food (3-5ml) was decanted into small 50ml vials. To 
prevent the food from getting solid too fast, each bottle was kept at 65°) in a water bath during the 
decanting process. The fly food was dried for a few hours or over night, covered with paper towels to avoid 
contamination, before finally the vials were plugged with anti-mite-plugs. The drug food was always 
prepared freshly once every 1 to 1.5 weeks. 
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3.2.4  Longevity assays 
All longevity assays were performed at 29°C. Flies were maintained at a density of 9-11 flies per vial. They 
were transferred to new fly food every 2 to 3 days. For the drug and genetic screening approximately sixty 
mated females were used. For the core experiments for each genotype and condition, approximately 
hundred mated females were used. The number of deceased flies was counted on every flipping day and 
documented in flytracker.gen.cam.ac.uk/. The overall lifespan is depicted in Kaplan-Meier curves and the 
median survival per vial (9-11 flies) is visualized as dot plots. Data analysis was conducted with GraphPad 
Prism 7.0a. 
 
 
3.2.5  Genotyping of transgenic f l ies  
To verify the presence of transgenes in newly generated double- or triple-transgenic fly lines, genomic 
DNA was extracted from adult flies and subsequently PCR analysis was performed in a 3-step protocol 
using DreamTaq DNA polymerase (Thermo Fisher Scientific) according to manufacturer´s instructions. 
For genomic DNA extraction, one fly per genotype was anesthetized with CO2 and transferred into a 
1.5ml Eppendorf tube on ice. Then, 50µl of genomic DNA extraction buffer (Table 3) was added to each 
vial. After squashing the fly with a pipette tip, the samples were incubated at 37°C for 30min, shaking, 
followed by a 2min incubation at 95°C for Proteinase K inactivation. Either 1 to 2µl per sample was used 
per PCR reaction (Table 13), either directly after genomic DNA extraction or after storing the sample at  
-20°C. The composition of the PCR reaction mix is depicted in Table 13. The PCR analysis was 
performed as described in Figure 14. PCR products were separated using agarose gel electrophoresis (1.2% 
agarose in 0.5x TBE buffer including HDGreenTM DNA Stain (Intas Science Imaging)). The GeneLadder 
(100pb and/or 250bp-10kb, GENAXXON bioscience) was used to determine the DNA fragment size 
under ultraviolet light in the E-BOX VX2 gel analysis chamber. 
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Table 13: PCR reaction mix per sample (25µl or 50µl): 
Volume for 25µl reaction (µl) Volume for 50µl reaction (µl) Name 
2,5  5 DreamTaqTM Green Buffer (10x) 
0.5 1 dNTP mix (10mM) 
0.5 1 Forward Primer (10µM) 
0.5 1 Reverse Primer (10µM) 
0.2 0.3 DreamTaq DNA polymerase 
1 2 DNA template 
to 25µl to 50µl water 
 
 
Table 14: PCR program 
Temperature Time 
95°C 3 min 
95°C 30 s 
x°C * 30 s 
72°C 1:30 min 
! 34 cycles 
72°C 10 min 
4°C ∞ 
*Annealing temperature adjusted for each primer pair as described in Table 11. 
 
 
3.2.6  Immunohistochemical  stainings  
Fly brains were dissected in PBS and afterwards incubated in 1 x PBS + 0.5% (v/v) Triton X-100 (PBST). 
This was followed by a fixation step in always freshly prepared 3.7% (w/v) formaldehyde solution (Sigma) 
in PBST for 30min. To wash out the fixation solution and for permeabilization, the fly brains were 
washed with PBST for 10min at RT for four times. For blocking, the brains were incubated in 5% (v/v) 
FBS in PBST for 30min at RT or over night at 4°C. To stain for total Aβ, the brains were incubated in 
the primary α-6E10 antibody (1:1000, Covance, Sig-39320-200 Lot: D11LF02498) for 2-3 days at 4°C, 
shaking. The antibody was removed by a 5-10min washing step in PBST which was repeated four times. 
This was followed by a two day incubation of the brains in the goat anti-mouse IgG (H+L) secondary 
antibody, Alexa Fluor® 568 conjugate (1:2500, Thermo Fischer Scientific) at 4°C, shaking. Thioflavin S 
(ThS, Sigma-Aldrich) was additionally added at this point in a final concentration of 5µM and co-
incubated with the secondary antibody. More detailed descriptions of amyloids/β-sheet plaque staining 
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with ThS can be taken from (Berg et al. 2010). After the final washing steps (4x10min, RT), the fly brains 
were mounted in VECTASHIELD® Mounting Medium without DAPI (Vector Laboratories) for 30min 
at RT. Translucent nail polish was used to seal the cover slips. Imaging of the fly brains was performed 
with the laser scanning confocal microscope LSM 780 (Zeiss). All shown images were processed using Fiji 
(Schindelin et al. 2012) and Adobe Illustrator CS6. 
 
 
3.2.7  Redox Analysis  of  f ixed and freshly dissected adult  f ly  brains 
The redox sensors (cytoGrx1-roGFP2, cyto-roGFP2-Orp1, mito-roGFP2-Orp1) were expressed in the fly 
brain using the Gal4/UAS expression system. The nSyb-Gal4 and elav-Gal4 or repo-Gal4 driver lines were 
used to drive expression of the redox sensors in all neurons or glia cells, respectively. Fly brains were 
dissected following the instructions from (Wu & Luo 2006). Briefly, the adult flies were anesthetized 
shorty, rinsed in 70% Ethanol (Sigma-Aldrich), transferred onto a dissection pad and fixed with a needle. 
To determine the responsiveness and the maximal attainable redox changes of the redox sensors to 
reducing and oxidizing conditions, I dissected fly brains in 1 x PBS and immediately transferred them into 
8-well Chambered Coverglass Systems (Thermo Fischer Scientific) containing 200µl 1x PBS + 0,1% 
Tween 20. The chambers with the brains were kept on ice. To fully reduce or to fully oxidize the probe, 2-
5mM (final concentration) of the reductant DTT (Carl Roth) or 2-5mM of the oxidant DA (Sigma-
Aldrich), was added to the brains for at least 30min on ice and 5-15min at RT (Figure 2). The fly brains 
were either imaged directly or fixed in 3.7% freshly prepared formaldehyde solution (Sigma) for 30min at 
RT, washed four times with 0.1% PBST, followed by 30min 20mM N-ethyl maleimide (NEM) treatment 
and finally embedding the brains in VECTASHIELD® Mounting Medium without DAPI (Vector 
Laboratories). To conserve the redox state of the redox sensors during the dissection process, I dissected 
the fly brains in NEM (Sigma-Aldrich) (Guan & Kaback 2007; Barata & Dick 2013; Fujikawa et al. 
2016). This alkylating agent binds to all reduced cysteins and therefore protects the sample from further 
oxidation by e.g. atmospheric oxygen. For live imaging of freshly dissected samples, I dissected the fly 
brains directly in Rinaldini´s solution (8mg/ml NaCl, 0.2mg/ml KCl, 0.05mg/ml NaH2PO4, 1mg/ml 
NaHCO3, 1mg/ml Glucose diluted in distilled water and sterile filtered, all components were obtained 
from Sigma-Aldrich, (Harzer et al. 2013)) containing 25mM NEM. I let the brains incubate for maximal 
1h on ice, while dissecting the other fly brains, and then directly imaged them. DTT, DA and NEM 
solutions were always prepared freshly and kept on ice. Live imaging of the fly brains was performed in the 
8-well Chambered Coverglass plates using the confocal microscope LSM 780 or LSM 880 (ZEN 2010 B 
SP1 or ZEN 2.1 Software). I used a Plan-Apochromat 20x/0.6 M27 objective and a T-PMT detector. The 
probe fluorescence was excited at 405nm and 488nm, sequentially, line by line and the detector range 
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detected from 499-534nm or 499-536nm. I used an averaging of 4, a bit depth of 16bit, a zoom of 0.6, a 
pinhole size (section thickness) of 3.5-4.0 µm, a gain of 790-910V and a digital offset of 0. The frame size 
was 512 x 512 pixels, and the scanning frequency “8-9” 1.52-1.58 µs. For each experiment all imaging 
setups were kept unchanged. 
 
 
 
 
 
Figure 2: Schematic overview of the workflow for redox analysis in fly brains. Imaging of freshly dissected fly 
brains, which were fully reduced or oxidized with DTT or DA, or treated with NEM, was performed with 
confocal microscopy. This was followed by image analysis, calculating the fluorescence intensity ratio 
405nm/488nm with ImageJ.  
 
 
3 .2.8  Cell  l ine and val idation of the redox analysis  in vitro  
For the validation of the redox sensors in vitro, I used Drosophila Schneider Drosophila Line 2 (S2) cells 
adapted in serum-free medium, which were maintained in Express Five SFM Medium (Life 
Technologies). Cells were grown at 25°C without CO2 in presence of 10% L-Glutamine (Sigma-Aldrich), 
100IU/ml penicillin and 100µg/ml streptomycin. One day before transfection 1x106 cells were seeded on 
0.5mg/ml Concanavaln A (Carl Roth)-coated glass cover slips in 24-well plates (Greiner Bio-One). 
Transfection was performed using the Effectene Transfection Reagent (Qiagen) according to 
manufacturer´s instructions, by applying 200ng plasmid of interest per well. The cells were transfected 
with each redox sensor (pCaSper4 cyto-Grx1-roGFP2, pCaSper4 mitoCOX8-roGFP2-Grx1, pCaSper4 
cyto-roGFP2-Orp1, pCaSper4 mitoCOX8-roGFP2-Orp1), kindly provided by the T.P. Dick laboratory. 
Three days after transfection, I treated the samples with 2-5mM DTT (Carl Roth) or 2-5mM oxidant DA 
(Sigma-Aldrich), which was followed by 20mM NEM treatment. The cells were fixed with 3.7% PFA, 
each for 10min at RT, followed by four washing steps with 1xPBS for 5min. The glass cover slips were 
mounted in VECTASHIELD® Mounting Medium without DAPI (Vector Laboratories). The fixed 
samples were imaged with a Zeiss LSM 780 confocal microscope using a Plan-Apochromat 63x/1.40 Oil 
DTT / DA NEM
Dissect brains
in PBS
Dissect brains
in NEM
Confocal microscopy
Image analysis
Fluorescence intensity ratio  =
I405nm
I488nm
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DIC M27 objective and a 1,5 x zoom (image size 89,8µm x 89,8µm). The detailed image processing and 
data analysis can be taken from 3.2.9.  
 
 
3.2.9  Image process ing and data analysis  for redox analysis  
For image processing ImageJ (Version 2.0.0-rc-49/1.51a) was used. First, the obtained confocal pictures 
were converted to 32-bit format. A threshold was set for the fluorescence intensities of the 405nm and 
488nm images and values below were set to “not a number” (NaN). To calculate the 405nm/488nm 
fluorescent intensity ratios, I divided the 405nm image by the 488nm image pixel by pixel. For 
comparison between different experiments I normalized the values to the fully reduced DTT sample = 0.2. 
The maximal attainable redox changes, also called dynamic range (DR), were calculated by dividing the 
405nm/488nm ratio from the fully oxidized DA sample by the fully reduced DTT sample. To calculate 
the degree of oxidation (OxD) of roGFP2, which gives information about the percentage of the pool of 
the redox sensor molecules that are in an oxidized state, I used the Nernst equation, as described 
previously (Meyer & Dick 2010): 
 OxDroGFP2 = ! R − RredI488redI488ox Rox − R + ! R − Rred ! 
 
The corresponding intracellular glutathione redox potential (EGSH), which is dependent on the OxD, was 
also calculated using the Nernst equation, with adaptations to the roGFP2 redox sensor and my recording 
conditions. E°´roGFP2 has been determined as –280 mV (Dooley et al. 2004): 
 !"#$ = !"#$%&2 = !°´!"#$%2 − !!"2! ! ln !!!"#$%&'(!!"#$%&'(!  
 
For the fluorescent ratio images shown in this study, I applied multiplicative Random J Gamma 3-7 and 
false colored the images using lookup table “Fire” to illustrate the redox changes in a more discernible way. 
 
 
3.2.10  Imaging and quantif icat ion of JNK activation of whole f ly  brains 
To monitor the JNK activation in response to Aβ in the fly brain I used the JNK reporter flies, kindly 
provided by the D. Bohmann´s laboratory (Chatterjee & Bohmann 2012). These reporter flies contain a 
stress-inducible promoter element (TRE) fused to the fluorescent reporter DsRed. For imaging of the JNK 
activation, I dissected the fly brains in Rinaldini´s solution and directly transferred them into an 8-well 
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plate filled with 200µl Rinaldini´s solution. The DsRed signal of the freshly dissected fly brains was 
directly imaged with the laser scanning confocal microscope LSM 780 (Zeiss) or Leica SP5. To ensure the 
comparability between the different data sets, I performed a time course analysis (Figure 13), where I 
dissected fly brains of different time points all on one day in four different imaging cycles. Per genotype 3-
5 brains were imaged and analyzed. For quantification, the DsRed fluorescent intensity of the whole image 
was measured, using Fiji (Schindelin et al. 2012). To monitor also minor differences in JNK activation in 
Aβ42 +/- Gclc-OE or Gclc-RNAi flies (Figure 13), I quantified the DsRed fluorescent intensity divided by 
the brain size. The plugin for Fiji, which I used to process the images in Figure 14, is depicted here: 
 
run("Rotate... ") 
wait(500); 
run("Subtract Background...", "rolling=100"); 
roiManager("Reset"); 
run("Select None"); 
run("Set Measurements...", "area integrated limit display redirect=None decimal=3"); 
run("Threshold..."); 
setAutoThreshold("Default dark"); 
setThreshold(209, 4095); 
waitForUser("Please check the Thr."); 
run("Measure"); 
 
run("Duplicate...", ""); 
run("Gaussian Blur...", "sigma=20"); 
wait(500); 
setAutoThreshold("Default dark"); 
setThreshold(32, 4095); 
waitForUser("Please check the Thr."); 
run("Analyze Particles...", "size=10000-Infinity pixel circularity=0.00-1.00 show=Nothing include 
summarize add"); 
run("Close"); 
roiManager("Select", 0); 
run("Enlarge...", "enlarge=-20 pixel"); 
run("Add to Manager"); 
resetThreshold(); 
run("Measure"); 
 
 
3.2.11  Extraction of soluble and insoluble Aβ from fly brain homogenates   
The mated female flies I used for protein extration were previously kept at -80°C. To decapitate the flies, 
the frozen whole flies were first transferred into a 15ml falcon tube. Afterwards, the falcon tubes were 
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immersed in liquid nitrogen, then vortexed and strongly tapped on the table. This was repeatedly executed 
four times. To get a yield of approximately 180-250µg total protein were used. The 20 or 30 decapitated 
fly heads were transferred into a mashing tube (CK14 – 0,5ml) and mashed in protein extraction buffer 
(Table 3) (1-1,3µl per fly head) using a Minilys personal homogenizer (Peqlab). Then the samples were 
sonicated for 5min on ice and mashed again. To avoid the formation of foam, the detergents 1% (w/v) N-
lauroylsarcosine, 1% (w/v) SDS and 1% (v/v) Triton X-100 were added to protein extraction buffer after 
the homogenization step. For lysing, the samples were sonicated and incubated on ice for 15min for each 
step. To remove the tissue debris, the samples were centrifuged for 5min, at 3800 x g at 4°C and the 
supernatant was subsequently transferred to a new tube. The amount of total protein in the samples was 
determined by Lowry protein assay (DC™ Protein Assay, BioRad), then concentrations were equalized and 
the desired amount of total protein was transferred into a new tube. To reduce disulfide bridges, I 
performed a 1h incubation step in 1% (v/v) β-Mercaptoethanol on ice and separated soluble (supernatant) 
and insoluble (pellet) protein fractions by centrifugation at 21000 x g at 4°C for 1h.  
 
 
3.2.12  Western Blot Analysis   
The soluble protein fraction was transferred into a fresh tube and was diluted 1:6 in Lämmli (5% β-
Mercaptoethanol, 0.01% bromophenol blue, 10% Glycerol, 2% SDS 60mM, Tris-HCl pH 6.8) and 
boiled at 95°C for 5min. The samples were then either stored at -20°C or directly loaded on a gel. The 
remaining insoluble protein fraction, as pellet, was furthermore resuspended and washed in 400µl protein 
extraction buffer (Table 3) including all detergents, followed by sonication for 15min on ice and 
centrifugation for 30min, 21000 x g at 4°C. This was repeated 3 times. Then, the pellet was solubilized in 
7,5µl 100% DMSO and incubated at 25°C for 1h, shaking, without pipetting up and down. Finally, I 
added 7,5µl of protein extraction buffer and 1:6 Lämmli, boiled the sample at 95°C for 5min and stored it 
at -20°C or directly loaded the samples on a gel. For gel electrophoresis the NuPAGE Novex 4-12 % Bis-
Tris gels and NuPAGE MES SDS Running Buffer (Thermo Fischer Scientific) and for semi-dry transfer 
the Amersham Protran 0.1 µm Nitrocellulose membranes (GE Healthcare) and the Trans-Blot® Turbo™ 
Transfer System (BioRad) were used. For antigen retrieval after the transfer, I boiled the membrane in 
PBS in a microwave for 1,5min and subsequently blocked the membrane in 5% (w/v) milk powder in 1x 
PBS + 0,1% Tween-20 for at least 1h at RT. For Aβ staining, I used the primary α-6E10 antibody (1:500 
or 1:1000, Covance, Sig-39320-200 Lot: D11LF02498). As loading control I used the primary α-Actin 
antibody (1:500, Sigma-Aldrich, A2228). The incubation of the membrane in the primary antibody was 
performed for least 2h at RT or overnight at 4°C. After the washing steps for 6 x 5min at RT, the 
secondary antibody (goat α-mouse IgG-HRP 1:2000 or goat α-rabbit IgG-HRP 1:3000, Thermo Fischer 
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Scientific) was added for 1h at RT. For visualization of the signal, the membranes were incubated in 
SuperSignal West pico or femto Chemiluminescent Substrate and imaged using a C-DiGit® Blot Scanner 
(LI-COR®). For quantification, the Aβ levels were normalized to Actin as loading control using the Image 
Studio Lite Software (LI-COR®). 
 
 
3.2.13  Enzyme-l inked immunosorbent assay (ELISA) 
For ELISA measurements, the soluble protein fraction was transferred into a new tube, diluted 1:1 with 
AlphaLISA Buffer I (pH = 7,4), containing 4M GdnHCl (Carl Roth), 50mM Tris (pH = 7,4), 1mM 
EDTA (Carl Roth), 1x protease inhibitor (Santa Cruz Biotechnology Inc.) and incubated for 1h at 25°C, 
shaking. To prevent interference of too high concentrations of GdnHCl with the ELISA detection kit, I 
further diluted the samples 1:1 in AlphaLISA Buffer III (pH = 7,4) without GdnHCl (Table 3), to achieve 
a final GdnHCl concentration of 2M. Then, I incubated the samples for 30min at 25°C, shaking, 
sonicated them for 5°C on ice and finally stored them at -20°C. For ELISA measurements, the insoluble 
protein fraction was prepared according to the Western Blot analysis protocol, with following 
modifications: after the centrifugation and washing steps, the pellet was incubated in 8µl AlphaLISA 
Buffer I for 1h at RT, shaking. The samples were further diluted 1:1 in AlphaLISA Buffer III to achieve a 
final GdnHCl concentration of 2M. At the end, the samples were incubated for 30min at 25°C, shaking, 
sonicated for 5°C on ice and finally stored at -20°C. Before using the AlphaLISA Detection Kit 
(PerkinElmer), I diluted all freshly thawed samples in 2M GdnHCl, in AlphaLISA Buffer III to a desired 
concentration of 400mM GdnHCl. Soluble and insoluble Aβ42 levels were measured in triplicates with the 
Aβ 1-x (human) AlphaLISA Detection Kit (PerkinElmer) according to the manufacturer´s instructions in 
triplicates. For this, I used the Corning 96-well microplates (#3642, Corning) and a FLUOstar Omega 
microplate reader (BMG LABTECH). For all ELISA measurements I used triplicates of each 5µl sample 
volume and a final end concentration of 200mM GdnHCl per well. The values were normalized to 
references values of AlphaLISA Buffer II (pH = 7,4), containing 400mM GdnHCl, 50mM Tris (pH = 
7,4), 1mM EDTA, 1x protease inhibitor, which was diluted in the well to a final concentration of 200mM 
GdnHCl. To calculate total Aβ42 levels, soluble and insoluble Aβ42 levels were added to each other. 
 
 
3.2.14  Statist ical  Analysis  
All presented data are shown as mean ± standard error of the mean (s.e.m.). Statistical analysis was 
performed with Excel and GraphPad Prism 7.0a software. The statistical significance was carried out using 
one-way ANOVA and Dunnett´s multiple comparisons test. All results were considered as statistically 
significant when p < 0.05 *, p < 0.01 **, p < 0.001 *** and p < 0.0001 ****.  
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4.  Results 
4.1 Establishment of redox analysis in Drosophila  Aβ aggregation models 
4.1.1  Validation of the redox sensors  in vitro  
To monitor perturbations in redox homeostasis in the fly system, I made use of four genetically encoded 
redox sensors (Barata & Dick 2013; Gutscher et al. 2013; Simone C Albrecht et al. 2011) and first 
validated them in vitro in Drosophila S2 cells. These sensors allow specific measurement of glutathione 
redox potential and hydrogen peroxide (H2O2) levels, either in the cytosol or mitochondria. This is 
enabled by the direct fusion of roGFP2 to either glutaredoxin 1 (Grx1) or oxidant receptor peroxidase 1 
(Orp1), redox proteins which specifically and reversibly mediate roGFP2 oxidation by oxidized 
glutathione (GSSG) or H2O2, respectively (Simone C. Albrecht et al. 2011). First, I transfected the cells 
with each sensor (cyto-Grx1-roGFP2, mito-roGFP2-Grx1, cyto-roGFP2-Orp1, mito-roGFP2-Orp1). To 
determine their responsiveness to reduction or oxidation, the samples were treated with the reductant 
Dithiothreitol (DTT, Carl Roth) or the oxidant Diamide (DA, Sigma-Aldrich) three days after 
transfection. The alkylating agent N-ethyl maleimide (NEM, Sigma-Aldrich) was administered 
immediately afterwards to prevent them from further oxidation. To monitor the changes in the fluorescent 
intensity ratios, as they are an indicator of changes in the H2O2 concentration or glutathione redox 
potential (EGSH) (Meyer & Dick 2010), the fixed samples were imaged with confocal microscopy (Zeiss 
LSM 780). The samples were excited sequentially at 405 nm and 488 nm and detected from 500-530nm, 
processed and analyzed as previously described (Simone C Albrecht et al. 2011). As depicted for the 
cytosolic H2O2 and EGSH sensor (Figure 3A and B), treatment with the oxidant DA resulted in an increase 
of the fluorescent intensity at 405nm and a decrease at 488nm, and reversed under reducing conditions. 
The increase in fluorescence intensity ratio 405nm/488nm indicates an increase in oxidation of the sensor. 
The degree of oxidation (OxD) can be calculated using the Nernst equation as described in (Meyer & 
Dick 2010), and ultimately gives information about the EGSH or H2O2 concentration. The maximal 
attainable redox changes (dynamic range, DR), which represents the rate of maximal oxidation and 
maximal reduction of the probe, was calculated by dividing the 405/488nm ratio from the fully oxidized 
DA by the fully reduced DTT sample and are depicted in Figure 3A` and B`. The sensitivity of the 
sensors to reducing and oxidizing conditions confirmed the suitability of the system for Drosophila cell 
culture experiments.  
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Figure 3: Validation of the cytosolic H2O2 (cyto-roGFP2-Orp1) and EGSH (cyto-Grx1-roGFP2) redox sensor in 
vitro in fixed samples. (A-B) S2 cells transfected with the H2O2 (A) and EGSH sensor (B). Single stack images are 
shown taken with a 63x/1.40 Oil DIC M27 objective and a 1,5 x zoom (image size 89.8µm x 89.8µm). Here are 
shown the 405nm/488nm fluorescent intensity ratios of the probes normalized to DTT = 0.2. DTT treatment 
decreased and DA treatment increased the 405nm/488nm ratio. The corresponding maximal attainable redox 
changes (dynamic range, DR) are depicted in A` and B` with the dynamic range of 2.5 – 3.5. Scale bars: 20µm.  
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4.1.2  Validation of the redox sensors  in vivo in f ly  brains 
To test the suitability of the redox sensors in our Drosophila in vivo system, the Gal4/UAS system (Brand 
& Dormand 1995) was used to express the redox sensors in all glia cells of the fly brain (Figure 4C-D) 
under the control of the repo-Gal4 promoter. Glia cells play an important role in the maintenance of 
neuronal glutathione levels (Sagara et al. 1993; Dringen, Pfeiffer, et al. 1999) and in pro-inflammatory 
processes contributing to oxidative stress conditions in AD (Liddelow et al. 2017; Heneka et al. 2014; 
Block et al. 2007). Investigating the role of glia cells in the context of AD and disturbed redox homeostasis 
is therefore of great importance. After dissecting the brains and treating them with the reductant, oxidant 
and alkylating agent as described above, fly brains were fixed and imaged using a confocal microscope. 
Afterwards, the 405nm/488nm fluorescent intensity ratios were determined. Figure 4C shows fly brains 
expressing the cytosolic H2O2 sensor and Figure 4D depicts fly brains expressing the cytosolic EGSH sensor 
in all glia cells. The corresponding DRs are shown in Figure 4C` and D`. The responsiveness of the redox 
sensors to reduction and oxidation in fixed fly brains confirmed the validity and the sensitivity in our 
Drosophila in vivo system. The complete protocol for DTT, DA, NEM treatment and imaging setups can 
be found in the Material and Methods section 3.2.7. 
To investigate redox changes on a cell-type specific level in neuronal and glial cells of the fly brain), these 
redox sensors were selectively expressed in either all neurons (using the nSyb-Gal4 promoter) or in all glia 
cells (using the Repo-Gal4 promoter). Although initial experiments validated our experimental setup in 
vivo, tissue sections showed a high variability of the redox states in different layers and differentiation 
between neurons and glia cells was insufficient. To better discriminate between neurons and glia cells, 
improve the different variability of previous redox analysis and furthermore to overall represent the whole 
fly brain with several combined z-stacks and not just as a single stack like performed in fixed tissue, the 
redox analysis was tested with freshly dissected fly brains instead of fixed samples. After dissecting, the 
unfixed and freshly dissected fly brains were oxidized with Diamide (2-5mM) and a reduced with DTT 
(2-5mM) and subsequently imaged by confocal microscopy. As illustrated for cyto-Grx1-roGFP2 
expressed in all glia cells (Figure 5A) and neurons (Figure 5B), treatment with the reducing agent DTT 
resulted in the expected increase in fluorescence intensity at 488nm and a decrease at 405nm, vice versa 
under oxidizing conditions. The maximal attainable redox changes are illustrated in Figure 5A` and B`, 
ranging from DR = 1.9 in neurons to DR = 2.9 in glia cells. The responsiveness of the redox sensor to 
reduction and oxidation confirmed the validity and the sensitivity of redox analysis in freshly dissected fly 
brains. Furthermore, by comparing redox analysis of the freshly dissected fly brains (Figure 5) with fixed 
tissue (Figure 4), no overall increase in the dynamic range was observed, however discrimination between 
neurons from glia cells was improved. Moreover, several z-stack pictures represent the whole brain without 
differences in the redox state in different layers of the fly brain. All redox analyses from now on were 
performed with freshly dissected fly brains. 
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Figure 4: Validation of the cytosolic H2O2 (cyto-roGFP2-Orp1) and EGSH (cyto-Grx1-roGFP2) redox sensor in 
vivo of fixed samples. (A-B) Under the control of the repo-Gal4 promoter the redox sensors were expressed in all 
glia cells of the fly brain. Single stack images are shown taken with a 10x/0.30 M27 objective and a 0.8 x zoom 
(image size 1060.7µm x 1060.7µm). Shown are the 405nm/488nm fluorescent intensity ratios of the probes 
normalized to DTT = 0.2. The dynamic range between fully reduced samples (realized with DTT treatment) and 
fully oxidized samples (realized with DA-treatment) varies from 2.0 using the cytosolic EGSH (A`), and 4.9, using 
the cytosolic H2O2 sensor (B`). False color scale (fire) was applied to all presented 405/488nm ratio images. Scale 
bars: 200µm.  
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Figure 5: Validation of the redox sensors in neurons and glia cells of freshly dissected adult fly brains. Under the 
control of the pan-glial repo-Gal4 or pan-neuronal nsyb-Gal4 promoter, the cyto-Grx1-roGFP2 redox sensor was 
expressed in all glia cells (A) or all neurons (B). The redox sensor responded to exogenously applied DTT and 
DA. Depicted are the 405nm/488nm fluorescent intensity ratios of the probes normalized to DTT = 0.2. To 
illustrate the redox changes in a more discernible way I applied multiplicative Random J Gamma 13 and used 
false color scale (fire) to all shown 405/488nm ratio images. The maximal attainable redox changes (dynamic 
range) are depicted in A` and B`. All confocal microscopy images are maximum intensity projections (MIPs). 
Scale bars: 200µm. 
 
 
4.1.3  Combining redox sensors  with Drosophila Aβ aggregation models  
To investigate cell-specific redox changes in the onset and progression of AD, I introduced the genetically 
encoded fluorescence proteins (Barata & Dick 2013; Gutscher et al. 2013; Simone C. Albrecht et al. 
2011) into our in vivo Drosophila Aβ aggregation models, to induce neurodegeneration. I used a tissue-
specific dual expression system to express different transgenes in neurons or glia cells, independently from 
each other. Aβ variants were expressed pan-neuronally (with the LexA/LexAop system) and redox 
sensors were co-express in neurons or glia cells (with the Gal4/UAS system) without crosstalk (Figure 6). 
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Figure 6: Schematic overview to perform redox analysis with redox protein coupled roGFP2s in adult fly brains 
combined with our in vivo Drosophila Aβ aggregation models. Using the tissue-specific dual expression system 
(Gal4/UAS and LexA/LexAop), we independently expressed toxic Aβ42 and less-toxic TAβ40 peptide under the 
control of the nSyb-LexA promoter in all neurons and co-expressed the redox sensor under the control of nSyb-
Gal4 or repo-Gal4 promoter pan-neuronal or pan-glial, respectively. 
 
 
The fast aggregating human Aβ42 peptide causes toxicity in the fly nervous system (Iijima et al. 2004; 
Speretta et al. 2012) and was used as a neurotoxic agent for this study (J Hardy & Allsop 1991; Karran et 
al. 2011). To exclude that protein accumulation per se is causing any redox stress, the TandemAβ40 
(TAβ40) variant was used as a direct negative control (Speretta et al. 2012). TAβ40 is a fast aggregating 
dimeric construct, consisting of two Aβ40 monomers linked via a twelve amino acid linker (Speretta et al. 
2012). While the monomeric Aβ40 variant is rapidly cleared due to its high turnover rate (Iijima et al. 
2004), the TAβ40 construct leads to the accelerated aggregation and consequent accumulation of Aβ40, but 
is not expected to cause strong toxicity (Speretta et al. 2012). Both Aβ42 and TAβ40 peptides are fused to a 
secretory signal peptide, leading to their secretion from neurons into the extracellular space, thereby 
mimicking the physiological situation in the human brain (Crowther et al. 2005). To confirm the 
aggregation properties of these two Aβ constructs, I quantified the levels of soluble Aβ and insoluble Aβ 
aggregates in fly head extracts (Figure 7A and Figure 7B). Western blot analysis showed that soluble levels 
of Aβ remained rather low in flies expressing the Aβ42 variant, while seven times higher levels were 
observed in TAβ40 expressing flies. However, increasing levels of insoluble Aβ42 were observed over time, 
with similar amounts of insoluble aggregates in TAβ40 flies and Aβ42 expressing flies at two weeks of age. 
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Figure 7: Confirmation of the aggregation properties of Aβ42 and TAβ40 in our Drosophila model. Soluble and 
insoluble Aβ levels are depicted in (A) and (B), respectively. Western Blot analysis revealed an accumulation of 
Sarkosyl- and SDS insoluble aggregated Aβ42 over time in Aβ42 flies (in days, B), while soluble Aβ levels nearly 
stay the same (A). The monoclonal 6E10 antibody was used for total Aβ detection and actin as loading control. 
 
 
To characterize the neurotoxic properties of accumulations consisting of these two Aβ variants, well-
established longevity assays were performed as a readout of the neurological integrity and an indirect 
readout for neurotoxicity of these flies (Burnouf et al. 2015; Luheshi et al. 2007; Iijima et al. 2004). 
Consistent with previous studies (Speretta et al. 2012), a dramatic decrease in the survival rate of flies pan-
neuronal expressing Aβ42 was observed (median survival = 14.9 +/- 0.4 days, Figure 8, black). In contrast, 
the pan-neuronal expression of TAβ40 only led to a slightly reduced survival rate (median survival = 36.2 
+/- 0.9 days, Figure 8, pink) compared to control flies (median survival of 44.5 +/- 0.5 days). To verify 
that the genetic background of the redox sensors does not severely alter the Aβ-mediated toxicity, the 
different Aβ variants were expressed in neurons and the redox sensors was co-expressed in either neurons 
or glia cells. Overall, co-expression of the cyto-Grx1-roGFP2 redox sensor in neurons Figure 8A) or glia 
cells (Figure 8B) does not strongly alter the survival of Aβ-expressing flies.  
 
 
Results 
 
44 
 
Figure 8: TAβ40 and Aβ42 variants differ in their neurotoxicity levels. Longevity assays show a strong neurotoxicity 
due to a decrease in life span of Aβ42 flies (black) and lower neurotoxicity in TAβ40 flies (pink) compared to 
control flies (blue). The genetic background of the redox sensors in neurons (A) or glia cells (B) does not strongly 
alter the life span of Aβ flies. Survival curves are depicted (n=60-120 flies per genotype). All error bars indicate 
s.e.m. Statistical analysis was performed with one-way ANOVA, *p ≤ 0,05, **p ≤ 0,01, ***p ≤ 0,001. 
 
 
To get further insights into the observed functional differences between these Aβ accumulations, 
immunohistochemical analysis of dissected fly brains was performed at day 12, shortly before Aβ42 
expressing flies start to die (Figure 8A). Confirming our biochemical analysis, staining for Aβ using the 
6E10 antibody revealed higher overall Aβ accumulation in TAβ40 over Aβ42. To specifically look at the 
deposition of β-sheet rich amyloid plaques, the amyloid specific dye Thioflavin S (ThS) was used (Berg et 
al. 2010). Importantly, almost no ThS positive staining was detectable in TAβ40 fly brains, whereas Aβ42 
fly brains showed overall very strong ThS positive staining (Figure 9). These data indicate that despite the 
comparable deposition of insoluble aggregates from both Aβ variants (Figure 7B), the structural features of 
these deposits have a differential impact on cellular viability (Figure 8A). Taken together, these data 
suggest the suitability of these Drosophila models of Aβ aggregation to investigate the impact of neurotoxic 
protein aggregates on the cellular redox homeostasis in a quantitative manner. 
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Figure 9: Amyloidogenic structures found in fly brains of Aβ42 flies. Immunohistochemical analysis of 12-day 
old fly brains showed the strong deposition of Thioflavin S (green) positive amyloidogenic structures in Aβ42 
flies, but not in TAβ40 flies. Total Aβ was stained with 6E10 (red). All confocal microscopy images are 
maximum intensity projections. Scale bars: 200µm. 
 
 
4.2 Analyzing the role of redox homeostasis and JNK stress response in 
Drosophila  models of Aβ aggregation   
4.2.1  Analyzing the changes in the redox homeostasis  in Drosophila  Aβ aggregation 
models .   
Before validating the redox analysis with freshly dissected fly brains, a proof of principle experiment was 
performed to test whether the aggregation of a very toxic Tandem Aβ42 (TAβ42) variant, a dimer consisting 
of two Aβ42 peptides (Speretta et al. 2012), could lead to changes in the neuronal redox homeostasis in 
these flies. Therefore, the four different redox sensors (cyto-Grx1-roGFP2, mitoCOX8-roGFP2-Grx1, 
cyto-roGFP2-Orp1, mitoCOX8-roGFP2-Orp1) were expressed and TAβ42 was co-expressed under the 
control of the elav-Gal4 promoter in all neurons, using the UAS-Gal4 single expression system. All fly 
brains were dissected in NEM, a cell permeable alkylating agent, which is necessary to block the redox 
state of the sensors to protect from further oxidation. The fixed brains were imaged, processed and 
analyzed as described by (Barata & Dick 2013; Simone C. Albrecht et al. 2011). Redox analysis of 5-6 day 
old flies revealed that compared to control flies, flies expressing TAβ42 showed a significantly increased 
glutathione redox imbalance in the cytosol (Figure 10A, purple) and mitochondria (Figure 10A, red) of 
neurons, indicated by the increase in the fluorescent intensity ratio (405nm/488nm). No significant 
differences in cytosolic or mitochondrial H2O2 levels were detected between control flies and TAβ42 flies 
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(Figure 10A, blue and green). Additionally, fly brains were dissected 5-6 days after hatching and 
subsequently stained for total Aβ using the monoclonal antibody 6E10 (Figure 10B). This showed that 
compared to control flies in TAβ42 expressing flies a strong 6E10 staining was observed. This proof of 
principle experiment shows that redox analysis in the fly brain can detect changes in the redox homeostasis 
upon Aβ accumulation and furthermore identifies an increase in the fluorescence intensity of the cytosolic 
and mitochondrial glutathione redox sensor, but not in the H2O2 sensors, in flies expressing TAβ42 
compared to control flies (Figure 10B).  
 
 
 
 
 
 
Figure 10: Changes in redox homeostasis can be studied in Drosophila Aβ aggregation models. (A) The elav-
Gal4 driver was used to express different redox sensors (cyto-Grx1-roGFP2, mitoCOX8-roGFP2-Grx1, cyto-
roGFP2-Orp1, mitoCOX8-roGFP2-Orp1) and co-express a very toxic and fast aggregating Tandem Aβ42 
(TAβ42) in neurons. The redox changes were analyzed in 5-6 day old flies (n=3-5 brains). All fluorescence 
intensity ratio (405nm/488nm) of the probe were plotted and normalized to respective DTT = 0.2 samples. All 
error bars indicate s.e.m. Statistical analysis was performed with one-way ANOVA, *p ≤ 0,05, ***p ≤ 0.001. (B) 
In addition fly brains were subsequently stained for Aβ using the monoclonal antibody 6E10 (red). Scale bar 
200µm. 
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4.2.2  Aβ42 deposit ion induces g lutathione redox potentia l  changes in neurons,  but 
not in gl ia  cel ls  
In order to monitor H2O2 and glutathione redox changes during the onset and progression of Aβ 
accumulation in these Aβ fly models over time, detailed time course experiments with live imaging in 
freshly dissected fly brains were performed and the cytosolic EGSH and H2O2 redox sensor were chosen. 
Due to the very strong toxicity and rapid death of flies expressing TAβ42 and to increase the time window 
for detailed time course analysis, the monomeric Aβ42 variant was used. This Aβ42 variant is also a fast 
aggregating and toxic variant, but less toxic than TAβ42. As in the previous experiments, the low toxic 
TAβ40 variant was used as negative control to exclude that protein accumulation per se is causing any 
redox stress. The intracellular H2O2 levels and glutathione redox potential (EGSH) was monitored over time 
using the cyto-roGFP2-Orp1 and the cyto-Grx1-roGFP2 redox sensors, respectively (Simone C. Albrecht 
et al. 2011). First detailed time course experiments were performed, where dissected fly brains were 
analyzed (see Methods for details) at four different time points of neurodegeneration (day 3, 6, 9 and 12). 
Here, neither an increase in cytosolic (Figure 11A and A`) nor mitochondrial H2O2 levels (Figure 12) was 
observed in flies expressing either TAβ40 or Aβ42. However, and most importantly, significant changes in 
the intracellular glutathione redox balance in neurons of Aβ42 flies were detected, indicated by an increase 
in 405nm/488nm fluorescence intensity ratio (Figure 11B) and EGSH (Table 15) using the cytoGrx1-
roGFP2 redox sensor. The degree of probe oxidation (OxD) (Figure 21) and the corresponding 
intracellular EGSH (Table 15) were calculated from the Nernst equation (Meyer & Dick 2010). This 
increase in EGSH specifically observed in neurons was already detected at an early time point (day 6), and 
further increased over time in parallel to the deposition of insoluble Aβ42 (Figure 7B). These changes in 
the EGSH of Aβ42 flies were not present in TAβ40 expressing flies (Figure 11B). With similar amounts of 
aggregated material in both Aβ fly lines, this finding suggest that the accumulation of protein deposits per 
se is not sufficient to evoke an increase in EGSH. However, accumulation of amyloids of the Aβ42 peptide is 
accompanied with significant changes in neuronal redox balance, as possible determinant of the 
consequently observed neurotoxicity and reduced fly survival (Figure 8). To further explore whether this 
effect is cell-type specific, this set of experiments were repeated in fly lines where Aβ expression is 
maintained by a neuronal driver (nSyb-Gal4), but where the redox sensors are specifically expressed in glia 
cells (repo-Gal4) (Figure 11). Because glia cells have shown to play an important role in the maintenance 
of brain homeostasis and in inflammatory processes, both in fly and human (Liddelow et al. 2017; Liu et 
al. 2015; Block et al. 2007), I was interested whether glia cells similarly respond to different Aβ 
accumulations. However, no changes in either H2O2 levels or EGSH in glia cells were observed (Figure 11A` 
and B`), indicating that neurons are particularly sensitive to redox stress evoked by Aβ42 deposition 
compared to glia cells. Taken together, the data show that changes in redox homeostasis are associated 
with Aβ42-mediated neurotoxicity and most interestingly are amyloid-deposit-, EGSH- and neuron-specific. 
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Figure 11: Quantitative redox analysis reveals glutathione redox changes only in neurons of Aβ42 flies. Redox 
analysis with the H2O2 redox sensor cyto-roGFP2-Orp1 (A, A`) and the EGSH redox sensor cyto-Grx1-roGFP2 
(B, B`) neurons (A, B) and glia cells (A`, B`) was performed in a time course (day 3, 6, 9, 12; n = 3-5 fly brains 
per time point and genotype). Flies expressing the less-toxic TAβ40 showed no redox changes whereas an 
intracellular glutathione redox imbalance could be detected in neurotoxic Aβ42 expressing flies. An increase in 
cyto-Grx1-roGFP2 fluorescence intensity ratio in neurons but not in glia cells over time was observed (B, B`, 
respectively). No changes in H2O2 levels neither in neurons nor in glia cells could be detected (B, B`, respectively) 
upon Aβ accumulation. Depicted are the 405nm/488nm fluorescent intensity ratio of the probe normalized to 
DTT = 0.2. All error bars indicate s.e.m. Statistical analysis was performed with one-way ANOVA, *p ≤ 0,05, 
***p ≤ 0.001, ****p ≤ 0.0001. 
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Figure 12: No changes in mitochondrial H2O2 levels upon Aβ deposition. Redox analysis with the 
mitochondrial H2O2 redox sensor mito-roGFP2-Orp1 in neurons, under the control of the nSyb-Gal4 promoter 
was performed in a time course (day 3, 6, 9, 12; n = 3-6 fly brains per time point and genotype). Graph 
representing the 405nm/488nm fluorescent intensity ratio of the probe normalized to DTT = 0.2. All error bars 
indicate s.e.m. Statistical analysis was performed with one-way ANOVA. 
 
 
Table 15: Overview of the effects of Aβ accumulation on EGSH (in mV) over time 
Genotype day 3 day 6 day 9 day 12 
Control – 340 – 313 – 315 – 310 
TAβ40 – 344 – 314 – 304 – 311 
Aβ42 – 311 – 300 – 297 – 293 
 
 
Using the dual expression system we co-expressed the cyto-Grx1-roGFP2 (under the control of the nSyb-Gal4 
promoter) sensor and two different Aβ variants pan-neuronal (under the control of the nSyb-LexA promoter). 
Compared to control flies, flies expressing the non-toxic TAβ40 showed no changes in EGSH, whereas flies 
expressing the neurotoxic Aβ42 showed an increase in intracellular EGSH, in neurons. The neuronal intracellular 
glutathione redox potentials (EGSH) were calculated from the Nernst equation, as described previously (Meyer & 
Dick 2010). E°′roGFP2 has been determined as –280 mV (Dooley et al. 2004).  
 
 
4 .2.3  Accumulation of Aβ42 leads to the activation of JNK stress  response 
Answering the question how changes in redox balance can be translated into a neuronal death-signaling 
cascade is of great importance. The JNK pathway is an important stress responsive pathway and has been 
linked to cell death in response to oxidative stress (Sclip et al. 2014; Tare et al. 2011; Marques et al. 2003; 
Jang & Surh 2002; Shoji et al. 2000) but also to stress tolerance (Liu et al. 2015; Wu et al. 2009; Wang et 
al. 2003). In the next step, the involvement of the JNK pathway and its connection to the observed 
glutathione redox imbalance in the Aβ aggregation models was analyzed. For this, the activation of the 
JNK pathway was monitored using a transgenic construct with stress inducible promoter elements fused to 
the DsRed fluorescent reporter (Chatterjee & Bohmann 2012). Here, JNK-mediated transcriptional stress 
response can be monitored in our Aβ Drosophila models by an increase in DsRed fluorescent intensity 
(Figure 13A). I observed that the JNK pathway is activated from day 6 onwards and was increased over 
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time in Aβ42, but not in TAβ40 fly brains (Figure 13B). The quantification is depicted in Figure 13C. This 
finding mirrors our previously observed EGSH changes (Figure 11B), illustrating that only the accumulation 
of amyloid deposits promotes stress responses. The progressive deposition of Aβ42 induces an increase in 
EGSH (Figure 11B) as well as the activation of the JNK pathway (Figure 13B, C), ultimately resulting in 
severe neurotoxicity (Figure 8). It is still under debate whether JNK activation contributes to neurotoxicity 
or acts as a neuroprotective factor in AD. The progressive increase in JNK activity, concomitant with Aβ42 
aggregation and glutathione redox imbalance over time supports the role for JNK in Aβ42-mediated 
toxicity as suggested by previous studies (Tare et al. 2011). Importantly, our data additionally provide in 
vivo evidence for the selective cellular toxicity for different protein aggregate conformations, which is 
mediated by the different activation of cellular stress response pathways by β-sheet-rich Aβ42 aggregates 
and less ordered Aβ40 deposits. 
 
 
 
Figure 13: Deposition of Aβ42 is associated with the activation of the JNK stress response. (A) Schematic overview 
of the stress-inducible promoter elements fused to the fluorescent reporter (TRE-DsRed-2R) (Chatterjee and 
Bohmann, 2012). (B) Time course analysis at day 3, 6, 9, 12 (n = 4 fly brains per time point and genotype) 
showed a JNK activation in Aβ42 fly brains (black), which was further increasing over time, but no JNK activation 
in TAβ40 flies (pink). Freshly dissected fly brains were directly imaged via confocal microscopy. Confocal 
microscopy images are shown as maximum intensity projections. Scale bar: 200µm. (C) Quantification shows the 
relative fluorescent intensity of the whole confocal microscopy image. All error bars indicate s.e.m. Statistical 
analysis was performed with one-way ANOVA, ***p ≤ 0.001. 
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4.3 Increased neuronal glutathione redox potential is  l inked to Aβ42-
mediated toxicity  
4.3.1  Manipulation of the glutathione synthesis  does not change JNK activation in 
Aβ42 f l ies  
To distinguish whether glutathione homeostasis is directly liked to neurotoxicity, or indirectly mediates 
this effect by activating the JNK stress-signaling pathway, I analyzed whether changes in glutathione 
synthesis influence the neurotoxic effect of Aβ42. First, the impact of modulating glutathione metabolism 
on JNK activation was investigated, by specifically manipulating the glutathione synthesis genetically as 
well as pharmacologically. To modulate neuronal glutathione levels, the glutamate cysteine ligase catalytic 
subunit (Gclc), first rate-limiting enzyme of the glutathione synthesis (Orr et al. 2005)was targeted. 
Importantly, neither the pan-neuronal overexpression of Gclc (Gclc-OE) nor the reduction of Gclc via 
RNAi (GclcRNAi), under the control of the nSyb-Gal4 promoter, led to significant changes in JNK 
activation in Aβ42 expressing flies 6 days post eclosion (Figure 14). The maximum intensity projections of 
confocal microscopy images are depicted in Figure 14A and the quantification of the relative DsRed 
fluorescent intensity is shown in Figure 14B. To confirm this disconnection between glutathione redox 
imbalance and JNK activation in Aβ42 flies, glutathione levels were modulated pharmacologically by 
administering Buthionine Sulfoximine (BSO), an inhibitor of the γ-glutamylcysteine synthetase, the 
second rate-limiting enzyme of the glutathione synthesis. Interestingly, also the pharmacological 
manipulation of glutathione synthesis did not result in any changes of JNK activation in Aβ42 flies (Figure 
18A), confirming the observations from the genetic manipulation experiment. This demonstrates that 
JNK stress signaling is not directly associated with changes in glutathione synthesis.  
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Figure 14: Genetic manipulation of the glutathione synthesis does not change JNK activation in 6-day old Aβ42 
flies. Genetic manipulation of glutathione synthesis in Aβ42 flies by pan-neuronal up- (purple) or 
downregulation (green) of the glutamate-cysteine ligase catalytic subunit (Gclc), driven by the pan-neuronal 
nSyb-Gal4 promoter and its effect on JNK activation (A, B). Confocal microscopy images are depicted in (A) 
Quantification of the relative DsRed fluorescent intensity divided by brain size (n=15-18 fly brains per 
genotype) depicted in (B). All depicted confocal microscopy images are maximum intensity projections. Scale 
bar: 200µm. All error bars indicate s.e.m. Statistical analysis was performed with one-way ANOVA, ****p ≤ 
0,0001. 
 
 
4.3.2  Manipulation of the glutathione synthesis  further increases  glutathione redox 
imbalance in Aβ42 f l ies   
To next investigate how manipulation of glutathione metabolism influences the glutathione redox balance 
in Aβ42 flies, redox analysis was performed in our Aβ42 cyto-Grx1-roGFP2 fly line after overexpressing or 
downregulating Gclc (Figure 15). Here, for pan-neuronal overexpression of Aβ42 and the redox sensor the 
UAS-Gal4 single expression system under the control of the elav-Gal4 driver was used. Redox analysis of 
12-day old Aβ42 flies +/- Gclc-OE revealed that Gclc-OE further increased the glutathione redox 
imbalance, indicated by the increased 405nm/488nm ratio of the cyto-Grx1-roGFP2 sensor (Figure 15B, 
purple) and a 22,7% increase in probe oxidation (Table 16), compared to Aβ42 flies. The downregulation 
of Gclc function, either genetically by GclcRNAi or pharmacologically via BSO treatment did not result 
in significant changes in glutathione redox balance compared to Aβ42 flies (Figure 15B, green and Figure 
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18B). These data indicate the increased glutathione synthesis does not buffer any effects mediated by Aβ42 
deposition, but in contrary exacerbates the effect and leads to increased OxD and EGSH (Table 16). 
 
 
 
 
 
 
Figure 15: Increase in EGSH upon Gclc-OE in Aβ42 flies. Genetic manipulation of glutathione synthesis in Aβ42 
flies by pan-neuronal up- (purple) or downregulation (green) of the glutamate-cysteine ligase catalytic subunit 
(Gclc), driven by the pan-neuronal elav-Gal4 and its effect on glutathione redox potential. (A) Redox analysis of 
12-day old Aβ42 flies with Gclc-OE showed an increase in the cyto-roGFP-Grx1 fluorescent ratio (n=15-17 fly 
brains per genotype) compared to Aβ42 flies without glutathione synthesis manipulation. Multiplicative J 
Gamma 7 and false color scale (fire) was applied to present 405/488nm ratio images. (B) The quantification is 
depicted in box plot, lower/upper quartile: whiskers, 5th/95th percentile. All depicted confocal microscopy 
images are maximum intensity projections. Scale bar: 200µm. All error bars indicate s.e.m. Statistical analysis 
was performed with one-way ANOVA, **p ≤ 0,01. 
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Table 16: Overview of the effects of genetic manipulation of GSH synthesis on EGSH (in mV) and life span 
Genotype OxDroGFP2 
[% roGFP2] 
EGSH  
[mV] 
Median life span 
[days] 
Control 33.1 ± 3.8 – 289 54.2 ± 1.2 
Aβ42 52.7 ± 5.2 – 279 16.5 ± 0.4 
Aβ42 + Gclc-OE 75,4 ± 5.4 – 266 11.5 ± 0.5 
Aβ42 + GclcRNAi 53.1 ± 2.9 – 278 19.8 ± 0.5 
 
 
The degree of roGFP2 oxidation (OxDroGFP2) and the corresponding intracellular glutathione redox potential 
(E
GSH
) were calculated from the Nernst equation, as described previously (Meyer & Dick 2010). E°′roGFP2 has 
been determined as –280 mV (Dooley et al. 2004). Median life span of control and Aβ
42 flies with and without 
glutathione synthesis manipulation is represented in days. We conclude that a further increase in E
GSH
 is 
associated with decreased life span//increased Aβ
42 neurotoxicity. 
 
 
4.3.3  Increased neuronal glutathione redox potentia l  i s  l inked to Aβ42 neurotoxicity 
Previous studies have shown beneficial effects of glutathione synthesis on life span of aging Drosophila 
(Orr et al. 2005). To investigate whether the modulation of the glutathione redox balance in Aβ42 
expressing flies also influences Aβ42 neurotoxicity, longevity assays (Figure 16A`) were performed. 
Intriguingly, increasing glutathione synthesis by Gclc-OE in Aβ42 flies resulted in a dramatically reduced 
life span of flies (Figure 16A, A` purple). In contrast, the life span of control flies remained unchanged by 
the manipulation of glutathione synthesis (Figure 17). Importantly, decreasing glutathione synthesis via 
GclcRNAi and BSO treatment was beneficial for fly survival and significantly prolonged life span of Aβ42 
flies (Figure 16A, A` green, Figure 18C, C` orange). These findings suggest that the neuronal EGSH directly 
impacts the neurotoxic stress signaling mediated by Aβ42 amyloid deposits.  
To further determine whether this redox imbalance is not only coupled to cell survival, but also to the 
levels of accumulating Aβ42, the levels of Aβ42 were analyzed in these fly lines with modified glutathione 
synthesis. Using sensitive ELISA methods to measure total, soluble and insoluble Aβ levels of these flies 
(Figure 16B, B`, B``), I however did not observe significant changes in the levels that would correlate with 
the dramatic decrease in the life span of these flies (Figure 16A, A`). Similarly, levels of Aβ42 were 
unchanged in flies treated with BSO (Figure 18D-D`) concluding that the observed changes in 
neurotoxicity are not solely based on changes in the level of Aβ42 in these fly lines, but rather directly relate 
to the EGSH. Taken together, these data suggest that an increase in the neuronal EGSH is directly linked to 
the cellular impact of Aβ42 deposition on neurons and is therefore a crucial regulator of Aβ42-mediated 
neurotoxicity. 
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Figure 16: Increased neuronal EGSH is associated with increased Aβ42 neurotoxicity. (A, A`) Survival assays, here 
using the dual expression system under the control of the nSyb-Gal4 promoter, revealed that glutathione redox 
changes (Figure 15) of Aβ42 flies with Gclc-OE were associated with a further decreased life span compared to 
Aβ42 only flies. n≥100 flies per genotype were used. Gclc-RNAi increased life span of Aβ42 flies (green), but did 
not change glutathione redox state (A, A`, green). ELISA assays of fly head extracts of 6-day old flies revealed 
that manipulation of the glutathione synthesis did not change total (B), soluble (B`) or insoluble (B``) Aβ levels. 
n=3 independent biological replicates. All error bars indicate s.e.m. Statistical analysis was performed with one-
way ANOVA, ****p ≤ 0,0001.  
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Figure 17: Genetically and pharmacologically manipulation of glutathione synthesis does not severely change life 
span of control flies. Genetically manipulation of glutathione synthesis with Gclc-OE or GclcRNAi in control 
flies. Gclc-OE does not change survivals of control flies, whereas GclcRNAi slightly increased survival of control 
flies. Survival curves are depicted in (A) and median survivals in (A`). Survival assays revealed that glutathione 
depletion with 1mM BSO did not change the life span of control flies. Flies treated with 1mM BSO are depicted 
in orange, control flies only in black. For survival assays n≥100 flies per genotype were used. All error bars 
indicate s.e.m. Statistical analysis was performed with one-way ANOVA,**p ≤ 0.01. 
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Figure 18: Pharmacological inhibition of glutathione synthesis in Aβ42 flies and its effects on JNK activation, 
EGSH, life span and Aβ levels. (A) No changes in JNK activation upon glutathione depletion with 1mM BSO in 
Aβ42 flies. Glutathione depletion with 1mM BSO (orange) did not change JNK activation in Aβ42 flies 
compared Aβ42 flies alone (black). On each time point (day 9 and 12), freshly dissected fly brains (n=4) were 
directly imaged with confocal microscopy. Quantification shows the relative DsRed fluorescent intensity of the 
whole confocal microscopy image, normalized to control flies (blue). (B) BSO treatment did not change the 
EGSH of 12-day old Aβ42 flies. Box plot representing the 405nm/488nm fluorescent intensity ratio of the cyto-
Grx1-roGFP2 probe normalized to DTT = 0.2 (n=8-10 fly brains per condition, lower/upper quartile; whiskers, 
5th/95th percentile). Survival assays revealed that treatment with BSO increased life span of Aβ42 flies. Survival 
curves are depicted in (C) and median survival in (C`). For longevity assays n≥100 flies per genotype were used. 
ELISA assays of fly head extracts of 12-day old flies revealed that glutathione depletion with 1mM BSO did not 
change total (D), soluble (D`) and insoluble (D``) Aβ levels. n=3 independent biological replicates. All error 
bars indicate s.e.m. Statistical analysis was performed with one-way ANOVA, **p ≤ 0.01, ***p ≤ 0.001. 
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4.4 Preliminary data of drug and genetic screenings for potential modifiers 
of Aβ42-induced neurotoxicity  
The here established Drosophila models could be used for large-scale drug and genetic screening platform 
to investigate potential mechanistic processes involved in the observed redox imbalance in Aβ42 flies 
(Figure 11) for future studies. In this last chapter, a small-scale screening was performed where different 
non-enzymatic, enzymatic antioxidants and other important players involved in redox homeostasis were 
tested and their potential influence on neurotoxicity was examined in Aβ42-expressing flies using longevity 
assays as readout. Preliminary data of candidate-based drug and genetic screenings are presented.  
For the drug screen, different drugs were tested. Three different survival rounds were performed, which 
are shown in Table 17 to Table 20. Oxidative stressors, such as Paraquat and H2O2 decreased life span of 
Aβ42-expressing flies. Unexpectedly, administration of well-known antioxidants such as NAC and α-
tocopherol decreased the life span of flies Aβ42. This worsening in Aβ42 neurotoxicity was also observed 
after administration of an inducer of the Nrf2 antioxidant pathway, tBHQ. Other antioxidants, such as 
ascorbic acid, L-4 Thiazolidinecarboxylic acid (TCA) and Nordihydroguaiaretic acid (NDGA) had no 
influence on the life span of Aβ42-expressing flies. The preliminary data of all tested conditions are listed in 
Table 17 to Table 20. 
 
 
Table 17: Overview of median survival of the small-scale drug screening in control and Aβ42-expressing flies: Part I 
Name Median Survival (days) Significance 
Experiment I: 
Holidic fly food 
0_control 44.1  
a_control + EtOH_2% (v/v) 48.0 0 n.s. 
1_Aβ42 19.5 0 **** 
2_Aβ42 + Paraquat_1mM 16.0 " 1 **** 
3_Aβ42 + NAC_10mg/ml 15.7 " 1 * 
4_Aβ42 + α-tocopherol_13.29mM 8.1 " 1 **** 
5_Aβ42 + ascorbic acid_0.36mM 19.0 1 n.s. 
6_Aβ42 + reduced GSH_0.22mM 19.0 1 n.s. 
7_Aβ42 + TCA_0.5% (w/v) 
[L-4 Thiazolidinecarboxylic acid] 
19.7 1 n.s. 
8_Aβ42 + NDGA_16.54mM 
[Nordihydroguaiaretic acid] 
18.5 1 n.s. 
9_Aβ42 + Propyl gallate_0.1mM 17.3 " 1 * 
Standard fly food 
b_control 52.3 0 ** 
c_Aβ42 16.1 y **** 
c_Aβ42 + C18 10% (w/v) 20.3 # x **** 
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For each survival assay approximately 100 female flies were used (n ≥ 100). All significances are compared to 1Aβ42 
flies and 2Aβ42 + EtOH 2% on holidic fly food or xAβ42 flies on standard fly food (one-way ANOVA Dunnett´s test). 
All significances are compared to 0control flies on holidic fly food or significance compared to ycontrol flies on 
standard fly food. Statistical analysis was performed using one-way ANOVA and Dunnett´s multiple comparisons 
test. Significantly increased life span (#) or decreased life span (") compared to respective Aβ42-expressing flies. 
 
 
Table 18: Overview of median survival of the small-scale drug screening in control and Aβ42-expressing flies: Part II 
Name Median Survival (days) Significance 
Experiment II: 
Holidic fly food 
Control 49.3  
Control + C18_10% (w/v) 39.5  0 ** 
Control + α-tocopherol_13.29mM 19.9  0 **** 
Aβ42 20.8 0 **** 
Aβ42 + EtOH_2% (v/v) 20.3 1 n.s. 
Aβ42 + DMSO_0.2% (v/v) 19.7 1 n.s. 
Aβ42 + α-tocopherol_13.29mM (wdh) 10.6 " 2 *** 
Aβ42 + α-tocopherol_6.7mM 9.4 " 2 **** 
Aβ42 + C18_10% (w/v) 21.4 1 n.s. 
Aβ42 + tBHQ_0.15 % (w/v)  11.9 " 1 ** 
 
All significances are compared to each 0 to control flies, 1Aβ42 flies, 2Aβ42 + EtOH 2%, 3Aβ42 + DMSO 0.2%. 
Significantly increased life span (#) or decreased life span (") compared to respective Aβ42-expressing flies. 
Significantly increased life span () or decreased life span () compared to respective control flies. Statistical 
analysis was performed using one-way ANOVA. For each survival assay approximately 100 female flies were used (n 
≥ 100). 
 
 
Table 19: Overview of median survival of the small-scale drug screening in Aβ42-expressing flies: Part III 
Name Median Survival (days) Significance 
Experiment III.a: 
Standard fly food 
Aβ42 17.1  
Aβ42 + EtOH-1_0.175% (v/v) 19.8 # 1 ** 
Aβ42 + EtOH-2_0.026% (v/v) 20.7 # 1 **** 
Aβ42 + α-tocopherol_1.1mM 19.0 " 7 ** 
Aβ42 + α-tocopherol_6.7mM (wdh) 18.0 " 6 *** 
Aβ42 + C18_10% (w/v) 19.2 # 1 * 
Aβ42 + tBHQ_0.15% (w/v) 6.7 " 1 **** 
Aβ42 + tBHQ_0.1% (w/v) 11.0 " 1 **** 
Aβ42 + H2O2_88mM 11.2 " 1 **** 
 
All significances are compared to 0control flies, 1Aβ42 flies, 6Aβ42 + EtOH-1 0.175%, 7Aβ42 + EtOH-2 0.026%, 8Aβ42 
+ EtOH-3 0.7%. Significantly increased life span (#) or decreased life span (") compared to respective Aβ42-
expressing flies. For each survival assay approximately 100 female flies were used (n ≥ 100). For statistical analysis 
one-way ANOVA was used.  
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Table 20: Overview of median survival of the small-scale drug screening in control flies: Part IV 
Name Median Survival (days) Significance 
Experiment III.b: 
Standard fly food 
Control 54.9  
Control + EtOH_0.175% (v/v) 56.5 0 n.s. 
Control + α-tocopherol_1.1mM 54.3 i n.s. 
Control + α-tocopherol_6.7mM 54.4  i n.s. 
Control + C18_10% (w/v) 54.8  0 n.s. 
Control + tBHQ_0.15% (w/v) 7.3  0 **** 
Control + tBHQ_0.1% (w/v) 10.4  0 **** 
Control + H2O2_88mM 10.1  0 **** 
 
For each survival assay approximately 100 female flies were used (n ≥ 100). All significances are compared to 0control 
flies and i control flies + EtOH-1 0.175%. Significantly increased life span () or decreased life span () compared 
to respective control flies. Statistical analysis was performed using one-way ANOVA. 
 
 
For the genetic screen, downregulation (DsRNA, TRiP and RNAi lines) and overexpression (OE lines) of 
various important players of the redox system was performed in the background of Aβ42-expessing flies 
(Figure 19). For a better presentation all tested candidate genes were grouped in seven different subgroups 
(Table 21) 1) Antioxidant enzymes important for the detoxification of hydrogen peroxide from cells and 
organisms 2) Enzymes of the thioredoxin and peroxiredoxin antioxidant system 3) Glutathione dependent 
antioxidant enzymes 4) Enzyme of the glutathione synthesis, 5) Enzyme of the pentose phosphate pathway 
(major source for NADPH) 6) Components of the Nrf2 antioxidant response pathway 7) Glutamate 
transporter. Each of the longevity assay rounds is depicted Figure 19 A-G. Among the 31 tested fly lines in 
the background of Aβ42 expression, 9 fly lines showed a significant increase in life span and in 9 fly lines a 
decrease in life span of Aβ42 flies was detected. All these lines, superoxide dismutase 1 RNAi line 1 
(24750), superoxide dismutase 2 DsRNA (24489), catalase overexpression (24621) but also catalase TRiP 
line 1 (43197), deadhead TRiP line (41857), and the cap-n-collar TRiP lines 1 and 2 (25984 and 40854) 
prolonged the life span of Aβ42 flies. Candidates that reduced the life span of Aβ42 flies were the second 
peroxiredoxin-5 overexpression line (W.Orr), the first thioredoxin reductase TRiP line (53883), the 
glutathione S-transferase D1 TRiP line (36818), the first glucose-6-phosphate dehydrogenase 
overexpression line (W.Orr), the transcription factor MafS (40853) and the excitatory amino acid 
transporter 1 overexpression line (8202). The overview of all preliminary survival results of all candidates 
and fly lines are listed in Table 21.  
Decrypting the complexity of the preliminary results of both small-scale screenings will be the task of 
future work. These datasets only provided a rough overview of the complex processes of redox homeostasis 
and their impact on the neurotoxicity of Aβ42. However, the here established models provide a suitable 
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screening platform to perform redox analysis and to analyze the activation of stress signaling pathways, 
such as the JNK pathway, for the future. 
 
 
 
Results 
 
62 
 
Figure 19: Overview of all seven redox survivals for the genetic screening for potential modifiers of redox-related Aβ42 
neurotoxicity. Longevity assays were performed in the background of Aβ42 with overexpression (OE) or 
downregulation (TRiP or RNAi) of various redox proteins. (A) Redox survival I (B) Redox survival II (C) Redox 
survival III (D) Redox survival IV (E) Redox survival V (F) Redox survival VI (G) Redox survival VI 
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Table 21: Overview of the survival data of the genetic screening in Aβ42-expressing flies 
Name Median Survival (days) Significance n-number Identification 
All Aβ42 from all seven survival rounds 
1Aβ42 (Redox survival I) 15.6 - 66 - 
2Aβ42 (Redox survival II) 16.3 - 63 - 
3Aβ42 (Redox survival III) 16.8 - 47 - 
4Aβ42 (Redox survival IV) 15.9 - 61 - 
5Aβ42 (Redox survival V) 14.5 - 102 - 
6Aβ42 (Redox survival VI) 15.0 - 112 - 
7Aβ42 (Redox survival VII) 16.5 - 112 - 
1) Antioxidant enzymes important for the detoxification of hydrogen peroxide from cells and organisms 
Aβ42 + SOD1-OE_1 15.5 1 n.s. 64 24754 
Aβ42 + SOD1-OE_2 15.8 3 n.s. 62 24750 
Aβ42 + SOD1_RNAi_1 18.3 # 2 ** 62 24493 
Aβ42 + SOD1_RNAi_2 15.9 2 n.s. 59 24491 
Aβ42 + SOD2-OE 16.4 2 n.s. 58 24494 
Aβ42 + SOD2_DsRNA 18.4 # 2 ** 65 24489 
Aβ42 + cat-OE 17.8 # 1 * 59 24621 
Aβ42 + cat_TRiP_1 18.8 # 2 *** 60 43197 
Aβ42 + cat_TRiP_2 17.7 2 n.s. 62 31894 
Aβ42 + PHGPx_TRiP 16.3 4 n.s. 64 41879 
2) Enzymes of the thioredoxin and peroxiredoxin antioxidant system: 
Aβ42 + Prx4-OE 15.0 3 n.s. 64 18489 
Aβ42 + dPRX5-OE_1 13.1 5 n.s. 95 W. Orr  
Aβ42 + PRX5-OE_2 13.0 " 5 * 102 W. Orr  
Aβ42 + TrxR_TRiP_1 15.3 2 n.s. 63 36805 
Aβ42 + Trxr1_TRiP_2 12.1 " 4 **** 63 53883 
Aβ42 + Trxr1_TRiP_3 14.2  4 n.s. 63 32984 
Aβ42 + dhd_TRiP 17.7 # 4 * 56 41857 
3) Glutathione dependent antioxidant enzymes: 
Aβ42 + GstD1_TRiP 15.6 3 n.s. 59 36818 
Aβ42 + GSTD1_TRiP (repeated) 13.0 " 5 * 100 36818 
Aβ42 + GSTsI4-OE 13.1 5 n.s. 98 A.J. Whitworth  
4) Enzyme of the glutathione synthesis: 
Aβ42 + Gclc-OE 9.1 " 5 **** 103 W. Orr  
Aβ42 + Gclc-OE (repeated) 9.5 " 6 **** 113 W. Orr  
Aβ42 + Gclc-OE (repeated) 11.5 " 7 **** 105 W. Orr  
Aβ42 + GclcRNAi 16.8 # 6 ** 111 W. Orr  
Aβ42 + GclcRNAi (repeated) 19.8 # 7 **** 109 W. Orr  
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5) Enzyme of the pentose phosphate pathway (major source for NADPH) 
Aβ42 + G6PD5c-OE_1 12.9 " 5 * 99 W. Orr  
Aβ42 + G6PD5c-OE_2 13.1 5 n.s. 103 W. Orr  
6) Components of the Nrf2 antioxidant response pathway: 
Aβ42 + cncTRiP_1 17.8 # 1 * 57 25984 
Aβ42 + cncTRiP_2 18.8 # 1 ** 64 40854 
Aβ42 + Keap1_TRiP 16.1 3 n.s. 73 57801 
Aβ42 + MafS_TRiP_1 11.9 " 3 **** 8 40853 
Aβ42 + MafS_TRiP _2 17.7 3 n.s. 84 25986 
7) Glutamate transporter 
Aβ42 + eaat1-OE_WT 6.1 " 3 **** 15 8202 
Aβ42 + eaat1_TRiP 15.3 3 n.s. 67 43287 
Aβ42 + eaat1_TRiP (repeated) 16.8 4 n.s. 61 43287 
Aβ42 + eaat2_TRiP 15.8 3 n.s. 40 40832 
 
All significances are compared to 1Aβ42 flies from Redox Survival I, 2Aβ42 flies from Redox Survival II, 3Aβ42 flies 
from Redox Survival III, 4Aβ42 flies from Redox Survival IV, 5Aβ42 flies from Redox Survival V, 6Aβ42 flies from 
Redox Survival VI, 7Aβ42 flies from Redox Survival VII. Statistical analysis was performed using one-way ANOVA 
and Dunnett´s multiple comparisons test. Significantly increased life span (#) or decreased life span (") of Aβ42-
expressing flies. 
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5.  Discussion 
5.1 Glutathione redox imbalance is an early event in AD pathology 
Numerous studies suggest that oxidative stress is connected to AD pathology (von Bernhardi & Eugenín 
2012; Cai et al. 2011). It is still not clear to what extend changes in the redox homeostasis contribute to 
the onset and progression of AD and whether there is a direct link between changes in redox balance and 
Aβ neurotoxicity. The discrimination of the oxidants and redox systems that are involved in Aβ 
neurotoxicity is crucial to better understand which pathways might be affected in AD pathology and 
therefore could be targeted for potential therapies against AD. Here, I present a versatile in vivo Drosophila 
model to address this question by combining cell-type-specific redox analysis, using genetically encoded 
glutathione and H2O2 redox sensors, with an AD neurodegeneration model based on the aggregation of 
the human Aβ42 peptide. A main finding of this study is the relevance of an increased cytosolic glutathione 
redox potential, which was already observed at an early time point of Aβ42 deposition (Figure 11B). This 
data indicates that glutathione redox imbalance is an early process in AD pathogenesis. This is consistent 
with previous studies, suggesting that oxidative damage in neurons is an early event occurring in AD 
pathology (Stephan et al. 2012; Mangialasche et al. 2009; Bermejo et al. 2008; Butterfield et al. 2007; 
Keller et al. 2005). In these studies, increased levels of protein carbonylation and lipid peroxidation were 
detected in early stage AD patients and in mild cognitive impairment (MCI) patients, who have a higher 
risk of developing AD. Furthermore, it has been reported that glutathione depletion is an early event 
already detectable in MCI and in mild AD patients (Mandal et al. 2015; Ansari & Scheff 2010; Bermejo 
et al. 2008), which supports and might provide an explanation for the increase in glutathione redox 
potential that was observed in our Aβ42 fly model. Whether this pro-oxidant shift in cytosolic glutathione 
redox potential results from a depletion of the total glutathione pool, an increase in oxidized glutathione 
(GSSG), or a combination of both, needs to be elucidated in future studies.  
Furthermore, one of the most intriguing question, whether oxidative stress has a causative role in AD 
pathogenesis or is a consequence of Aβ accumulation is still highly debated in the literature (Andersen 
2004). Several studies suggest that oxidative stress has a causal role in AD pathology and precedes Aβ 
plaque formation (Lin & Beal 2006; Praticò et al. 2001), whereas other work shows that Aβ aggregation 
precedes oxidative stress which is therefore a consequence of AD pathology (Xie et al. 2013). I tried to 
shed light on this intriguing question by performing a detailed time course redox analysis dissecting Aβ-
expressing fly brains at early and later stages of disease progression. This data showed, that the glutathione 
redox imbalance was already detectable at an early time point of Aβ42 aggregate formation (at day 6), but 
occurred after I observed the first depositions of Aβ42 aggregates in the fly brain from day 3 on. This 
supports redox changes may be a consequence of Aβ42 aggregation. More detailed time course analysis of 
young flies and employing temperature sensitive expression systems to switch Aβ expression on and off in 
Discussion 
 
66 
combination with monitoring the deposition of amyloidogenic structures using amyloid-specific polymer 
probes like p-FTAA or ThS stainings (Berg et al. 2010; Åslund et al. 2009; LeVine 1999) in more detail 
might give more insights into surely answering this question. 
 
 
5.2 Changes in glutathione redox potential,  but not in H2O2 concentration, 
are l inked to Aβ42-induced neurotoxicity 
There is accumulating evidence that mitochondrial dysfunction and its resulting ROS overproduction is 
correlated with AD pathology (Verri et al. 2012; von Bernhardi & Eugenín 2012; Lin & Beal 2006). 
Previous in vitro studies have shown, that H2O2 is generated during early stages of Aβ aggregation and can 
mediate Aβ protein toxicity (Tabner et al. 2005; Behl et al. 1994). In this thesis, I did not measure any 
changes in cytosolic or mitochondrial H2O2 levels, neither in neurons (Figure 11A, Figure 12), nor in glia 
cells (Figure 11A`). The lack of datable changes in H2O2 concentration in this in vivo model, strongly 
suggest that H2O2 levels are not the major factor in neurons or glia cells for the Aβ42-mediated 
neurotoxicity. Whether an accumulation of other ROS species or reactive nitrogen species (RNS) are 
involved in Aβ42-mediated neurotoxicity in this model, needs further investigation. As for example, nitric 
oxide (NO) has already been linked to AD pathogenesis as an important mediator of Aβ-induced neuronal 
cell death (Vodovotz et al. 1996; Hashimoto et al. 2002; Kadowaki et al. 2005). Thereby, using other 
ROS and NO detection methods, like Mitosox or DCFDA (Eruslanov & Kusmartsev 2010; Robinson et 
al. 2008) and DAF-2 DA or genetically encoded NO$ probes (geNOps) (Kojima et al. 1998; Eroglu et al. 
2016), could help to shed light on this open question in more detail. Furthermore, I cannot exclude that 
any other forms of mitochondrial dysfunction occur in this model, e.g. morphological changes or 
disruption of functional mitochondria including mitochondrial fragmentation, which has been published 
by Knott et al (Knott et al. 2008). The limitation of the H2O2 redox sensor (Orp1-roGFP2) used in this 
study is that it cannot measure H2O2 changes in the nano- or picomolar ranges. Peroxiredoxin-based redox 
sensors which posses higher sensitivity would need to be validated in the background of our Aβ 
aggregation models to address this question (Fujikawa et al. 2016; Sobotta et al. 2014). There could be 
small changes in H2O2 concentration that I cannot detect. Still it would need to be elucidated whether 
and to what extent potential nano- or picomolar H2O2 changes could contribute to the neurotoxicity 
mediated by Aβ42. 
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5.3 Aβ42 deposition induces glutathione redox potential changes in neurons 
but not in glia cells  
Interestingly, expression of Aβ42 in neurons and co-expression of the redox sensors in neurons or glia cells, 
revealed that the glutathione redox imbalance observed in the fly brain, which occurs in parallel to the 
deposition of Aβ42, is mainly observed in neurons, but not in glia cells (Figure 11B and Figure 11B`, 
respectively). It has been reported that neurons maintain their glutathione levels by the uptake of cysteine 
or precursors provided by glia cells (Sagara et al. 1993; Dringen, Pfeiffer, et al. 1999). Neurons with their 
relatively low levels of antioxidants are more sensitive and vulnerable to oxidative stress compared to glia 
cells which contain higher amounts of glutathione and have a more efficient peroxide detoxification 
system (Dringen, Kussmaul, et al. 1999; Iwata-Ichikawa et al. 1999; Dringen 2000; Yu et al. 2016). This 
increased resistance to redox stress of glia cells, could be an explanation why I did not observe any 
cytosolic glutathione redox imbalance or H2O2 level changes those cells. Whether this is due to their 
higher levels of glutathione (Sagara et al. 1993), their up-regulation of glutathione synthesis upon stress 
(Iwata-Ichikawa et al. 1999), or shutting down the supply of cysteine to neurons or because of an 
increased release of more oxidized glutathione (Hirrlinger et al. 2001; Morgan 2012; Ye et al. 2015) needs 
to be elucidated. The fact that in this fly model glia cells do not respond to the accumulation of Aβ42 with 
redox changes does not mean, that glia cells do not react or contribute to the neurotoxic effect of Aβ42 at 
all. I do not exclude, that glial dysfunction and inflammatory processes are initiated, including the release 
of pro-inflammatory cytokines, potentially leading to the activation of other stress response pathways, 
which could increase neuronal vulnerability to Aβ42 and therefore could be involved in Aβ42-induced 
toxicity (Wyss-Coray & Rogers 2012; Wyss-Coray & Mucke 2002). The exact mechanism, which 
mediates the crosstalk between neurons and glia cells remain a very important open question for future 
studies.  
 
 
5.4 Accumulation of Aβ42 results in the activation of the JNK stress 
response  
The literature is not consistent concerning the role of JNK signaling in AD. On the one hand it has been 
reported that the activation of JNK contributes to cell death in response to oxidative stress (Sclip et al. 
2014; Tare et al. 2011; Marques et al. 2003; Jang & Surh 2002; Shoji et al. 2000) and on the other hand 
that it can also protect against it since it is involved in stress tolerance (Liu et al. 2015; Wu et al. 2009; 
Wang et al. 2003). In the presented work, I observed an increase in JNK activation in Aβ42 flies over time 
(Figure 13), which supports its role in neuronal stress signaling upon Aβ42 deposition and confirms the 
activation of JNK signaling in the progression of AD pathology. However, I did not observe a further 
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increase in JNK activation in Aβ42 flies with increased glutathione synthesis by pan-neuronal Gclc-OE 
(Figure 14) with accompanied elevated toxicity (Figure 16A), suggesting that JNK activation is not 
directly associated with glutathione-mediated toxicity in this Aβ aggregation model. In this study, I did 
not observe a further increase of JNK activation upon glutathione depletion (via GclcRNAi or BSO 
treatment), which has been reported to trigger JNK activation (Fratelli et al. 2005; Yue et al. 2006; Franco 
et al. 2007; Circu & Aw 2012). Whether other factors are involved in glutathione-mediated Aβ42 toxicity, 
such as glutathione-S-transferase pi (GST-π), which catalyzes the conjugation of glutathione to 
electrophilic substances and is known to regulate JNK activation in cancer (Adler et al. 1999; Laborde 
2010) would be very interesting for further analysis. Looking at the involvement of other important stress 
pathways, such as the NF-E2-related factor-2 (Nrf2) pathway or the activation of death receptors like 
TNF-alpha, might also be of interest for future studies (Le Gal et al. 2015; Sayin et al. 2014; DeNicola et 
al. 2011). Manipulation of glutathione synthesis (via Gclc overexpression or GclcRNAi and BSO) did not 
influence JNK activation and neuronal EGSH, suggesting JNK pathway activation happens in parallel to 
changes in the overall redox balance. But gaining a comprehensive understanding of the relationship 
between glutathione synthesis and JNK activation in the background of AD could be highly interesting.  
 
 
5.5 Changes in glutathione redox imbalance is l inked to Aβ42-mediated 
neurotoxicity 
Most importantly, this study suggests a link between glutathione redox potential and Aβ42-mediated 
neurotoxicity. Intriguingly, an increase in neuronal glutathione levels in Aβ42 flies via pan-neuronal Gclc-
OE further exacerbates Aβ42 neurotoxicity, as life span was even more decreased (Figure 16A and Figure 
16A`) compared to Aβ42-expressing flies without glutathione synthesis manipulation. This was 
accompanied with a further increase in glutathione redox potential (Figure 15), indicating a direct 
mechanism for glutathione-synthesis manipulation-induced neurotoxicity, as ELISA assays did not reveal 
significant changes in the levels of Aβ42 in flies overexpressing Gclc (Figure 16B-B``). 
Moreover, the data indicate glutathione redox homeostasis is playing an important role in the cellular 
vulnerability to proteotoxic stress and might represent the missing factor that might explain to the fact 
that the Aβ plaque load in the brain does not directly correlate with the clinical symptoms of AD patients 
(Perez-Nievas et al. 2013; Sloane et al. 1997). Even though it has been reported that an increase in 
glutathione levels can be protective against ROS, increase cell viability (Luchak et al. 2007; Orr et al. 
2005) and overexpression of Gclc extends life span in wild-type Drosophila flies (Orr et al. 2005), in the 
context of the here presented Aβ aggregation model opposing effects were observed. There is only limited 
data on the function of glutathione available besides being a generic antioxidant there. Interestingly, in the 
Discussion 
 
 69 
context of neurodegeneration Duffy et al. (2014) have also linked an increase in glutathione levels with 
cognitive impairment in MCI patients. They observed high levels of glutathione in MCI patients 
compared to control patients, and that these higher levels of glutathione were associated with worsened 
neuropsychological performance, including verbal memory consolidation (Duffy et al. 2014). They 
suggested the increased levels of glutathione as an initially compensatory mechanism to adapt and respond 
to a subsequent injury (e.g. coping with increased oxidative stress), which is then followed by a decline in 
antioxidant levels. Furthermore, it has been shown in cultured cells that NAC treatment or overexpression 
of Gclc, resulting in higher levels of glutathione, caused glutathione-dependent reductive stress that 
triggered mitochondrial oxidation and caused in cytotoxicity (H. Zhang et al. 2012). Recently, reductive 
stress has been described to be a compensatory effect to oxidative stress, and has been reported to play a 
role in AD (Lloret et al. 2016; Badía et al. 2013; Russell et al. 1999). Whether reductive stress and 
subsequent mitochondrial oxidation are the cause for our observed enhanced toxicity in Aβ42 flies with 
Gclc-OE needs further investigation. Additional supporting evidence that an increase in antioxidants can 
also evoke negative effects was described in the context of cancer. Previous studies show, that increasing 
the levels of antioxidants or over-activating antioxidant pathways can result in increased tumorigenesis, 
tumor growth and invasiveness (Le Gal et al. 2015; Sayin et al. 2014; DeNicola et al. 2011). Additionally, 
clinical trials administrating antioxidants as potential treatment for AD at this point have not been 
successful in slowing down AD progression (Mecocci & Polidori 2012; Galasko et al. 2012; Kryscio et al. 
2017).  
The exact molecular mechanism of glutathione-synthesis manipulation-induced neurotoxicity in our Aβ42 
fly model could not be elucidated in this study, but our observations provided stimulating incitements 
into redox-associated mechanisms and specifically identified glutathione metabolism as a promising 
therapeutic target for the treatment of AD. The protein glutathionylation status of the proteome is an 
important post-translational modification cysteine residues by addition of glutathione to protect proteins 
from oxidative damage (Dalle-Donne et al. 2009), plays an important role in regulating redox homeostasis 
and has been described to be a critical regulator of apoptosis (Dalle-Donne et al. 2009; Franco & 
Cidlowski 2009). Investigating the protein glutathionylation status might give rise to more detailed 
mechanistic information. Previous studies have identified an increase in S-glutathionylated proteins in AD 
patients compared to age-matched controls (Newman et al. 2007). Another study, using mice brains and 
blood samples, suggested that the protein glutathionylation status can be used as a biomarker of AD 
progression and for early stage screening indicating its important role in AD (C. Zhang et al. 2012). 
Therefore, it would be very interesting to test whether the glutathionylation status of directly influences 
the glutathione redox potential of the cell. 
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Figure 20: Schematic graphic of main findings of this thesis, describing that changes in glutathione redox imbalance 
are linked to Aβ42 neurotoxicity. Pan-neuronal expression of Aβ42 caused a decrease in life span, which was 
accompanied with an increase in EGSH. An increase in glutathione synthesis worsened this phenotype. This study 
proposes additional roles of glutathione beyond the generic neuroprotective antioxidant and being involved in the 
Aβ42-induced neurotoxicity. 
 
 
5.6 Established Drosophila models provide screening platform for redox-
related and non-redox-related potential modifiers of Aβ42 neurotoxicity 
To investigate potential mechanistic processes behind our observations, preliminary drug (Table 17 - 
Table 20) and genetic (Table 21 and Figure 19) screenings were performed and longevity assays were used 
as read out. Due to the complexity of the preliminary results of the screening, I only describe a few 
candidates that might stimulate interest for future research projects. In both screenings some reflective but 
interesting preliminary results were observed that might be of interest for upcoming research studies and 
might give another perspective on how changing the redox homeostasis can influence the neurotoxic 
effects of Aβ42. One interesting preliminary result hinted towards the potential importance of the Nrf2 
pathway, a widespread transcriptional antioxidant response pathway (Le Gal et al. 2015; Sayin et al. 2014; 
DeNicola et al. 2011). Administration of an Nrf2 activator, tert-Butylhydroquinone, reduced life span of 
Aβ42-expressing flies (Table 18, Table 19) while downregulation of cap-n-collar (cnc), the Drosophila Nrf2 
ortholog (Sykiotis & Bohmann 2008; Lacher et al. 2016), via cnc_TRiP increased their life span of flies 
expressing Aβ42 (Table 21). As Nrf2 activation via tBHQ feeding also compromised the life span of 
control flies (Table 20) future studies should test lower concentrations of this Nrf2 inducer to confirm my 
preliminary observations and to exclude potential unspecific effects, which are not related to Aβ42. But the 
spark for future investigations is still given, because the Nrf2 pathway is connected to glutathione 
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metabolism, as it has been shown that Nrf2 activation leads to increased glutathione levels and Gcl mRNA 
levels (Steele et al. 2013). Interestingly, recent studies also showed the negative aspect of increased tumor 
invasiveness and tumor growth due to Nrf2 over-activation in (Le Gal et al. 2015; Sayin et al. 2014; 
DeNicola et al. 2011). Therefore, it might be very interesting to further investigate the interconnection 
between Nrf2 and glutathione synthesis manipulation-induced neurotoxicity in Aβ42 flies, which might 
help to decipher the exact mechanism behind our observations. 
Another interesting observation was detected after the administration of α-tocopherol and NAC, both 
well-known and often applied antioxidants (Miquel et al. 1982; Sung et al. 2004; Di Domenico et al. 
2015). Furthermore, it has been observed that the administration of Vitamin E improved cognitive 
dysfunction or slowing down clinical progression (Sano et al. 1997; Dysken et al. 2014). However, our in 
model Aβ42 aggregation did not confirm these previous studies since the feeding of α-tocopherol and NAC 
decreased the life span of Aβ42-expressing flies (Table 17 - Table 20). Control flies showed no changes in 
life span in the case of α-tocopherol. Whether NAC has the same effect on control flies without Aβ42 
expression, must be tested in upcoming studies. To be mentioned again that these are only preliminary 
data and need to be confirmed in future studies.  
A limitation of this screenings was that almost no titration of the drugs was performed. Our model 
overexpresses human Aβ42 fused to a secretion signal, which limits our model to the aggregation of Aβ42 in 
the extracellular space. But how the treatment of these different compounds influence Aβ42 generation, 
release or degradation might be interesting to investigate for future studies. On the first glance, these single 
preliminary results seem to be non-intuitive, but looking at the whole picture, this data are also very 
exciting, because the antioxidant NAC, and the activation of the prominent antioxidant pathway Nrf2 via 
tBHQ also caused a severe worsening of the life span of Aβ42-expressing flies. These data indicate that the 
overall notion that pro-antioxidant conditions are only neuroprotective could be critically questioned. I 
hypothesize that messing around with the redox system in the background of pathological conditions 
might be detrimental in both ways, having too much pro-oxidant or pro-antioxidant conditions. The data 
of this screening must be seen very critically, because the point of criticism of these small-scale screenings 
was, that also control flies showed unexpected decrease in life span in some of these cases. To decipher, 
whether the negative effects on survival rate of these compounds can be confirmed, lower concentrations 
of these drugs must be administered, where the effect on control flies are not significantly changing to 
make sure that the observed life span changes are in fact Aβ42-dependent. Additionally, the time point of 
drug administration might be crucial. Another limitation of the drug screenings was that the glutathione 
redox potential could not be reduced with any drug treatment (preliminary data not shown). For future 
studies, I suggest the genetic approach might be more promising. This might give more information of 
what is happening with fewer side effects and more and targeted manipulations. The preliminary data of 
the genetic screening showed that downregulation of cnc, SOD1, SOD2 and catalase (using following 
Discussion 
 
72 
Aβ42-expressing fly lines with cnc_TRiP_1, cnc_TRiP_2, cat_TRiP_1, SOD1_RNAi_1 and 
SOD2_DsRNA) increased in life span of Aβ42-expressing flies (Table 21 and Figure 19). This does not 
confirm previous studies showing that downregulation of these candidates worsen AD pathology 
(Murakami et al. 2011; Li et al. 2004; Gsell et al. 1995). Knockdown of antioxidant enzymes, such as the 
cytosolic and mitochondrial superoxide dismutase (SOD1 and SOD2, respectively) and catalase (Cat) have 
been shown to increase amyloid plaque load and worsen cognitive functions in AD transgenic mouse 
models (Murakami et al. 2011; Li et al. 2004; Gsell et al. 1995). Interestingly, in our model 
downregulation of SOD1 (Aβ42 + SOD1_RNAi_1) and SOD2 (Aβ42 + SOD2 DsRNA) resulted in a 
prolonged life span of flies expressing Aβ42 or in no difference in life span (Table 21, Figure 19B). 
Paradoxically both, overexpression and downregulation of catalase showed an increase or no significant 
changes in the life span of Aβ42-expressing flies.  
Testing higher number of RNAi and overexpression lines of each candidate, maybe with and without the 
combination of antioxidants and oxidants treatment, and then measuring the glutathione redox potential 
and H2O2 concentrations of these flies in the background of Aβ42 deposition might be very interesting. For 
upcoming studies, also control survivals must be performed, to identify the Aβ42-dependent changes. 
Finding out how a decrease in the glutathione redox balance can be achieved in the background of Aβ42 
accumulation and whether this is directly translated into a further increase in life span, might give some 
more insights into the mechanistic processes and could be followed up in future studies.  
In summary, preliminary data of both small-scale screenings in some cases showed non-consistent and 
contra-intuitive results. They emphasized the complexity of redox homeostasis and its mechanisms, 
seeming not easily to be unraveled and calling upon more critical thinking on the application of 
antioxidants. Nevertheless, the screenings provided a few potential and promising targets to look into in 
following studies. Even though this thesis could not provide detailed mechanistic processes that are 
involved in the observed redox imbalance the Aβ42-aggregation model, it provided a suitable screening 
platform with a few potential and promising targets giving spark for future investigations. 
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6.  Outlook & Conclusion 
This study provides new evidence for the relevance of redox signaling events in the onset and progression 
of AD. The development of versatile models, which are presented in this study, that combine redox 
analysis with Drosophila models of Aβ aggregation, will help deciphering these complex mechanisms and 
present a significant advance to the field of redox biology and neurodegeneration research. The main 
contribution of this study was to identify the direct link between glutathione redox potential and Aβ42 
neurotoxicity in vivo (Figure 20), which opened exciting insights into its involvement in Aβ42-mediated 
neurotoxicity. In contrast to the common view of “oxidative stress”, this thesis suggests additional roles of 
glutathione in addition to a generic antioxidant and proposes that the increase in neuronal glutathione 
redox potential is not just a byproduct of Aβ-mediated redox stress but might be an important regulator of 
Aβ42 neurotoxicity. Furthermore, this study also points out that the regulation of redox homeostasis and 
its impact on diverse diseases like AD is very complex, sometimes even paradoxical and needs more critical 
examination (Table 17 - Table 20) (Le Gal et al. 2015; DeNicola et al. 2011). Taken together these data 
also demonstrate that we need to be cautious with manipulations of the antioxidant system in AD disease 
background without knowing all side effects emerging from changing the redox balance. Especially since 
clinical trials administrating antioxidants as potential treatment for AD at this point have not been very 
promising in slowing down AD progression (Mecocci & Polidori 2012; Galasko et al. 2012; Kryscio et al. 
2017) and other studies link increased glutathione levels in MCI patients with increased cognitive 
impairment (Duffy et al. 2014). It might be very interesting to look at the cellular protein 
glutathionylation status, which has been reported to act protective against oxidative damage (Dalle-Donne 
et al. 2009) and found to be increased in AD patients (Newman et al. 2007). This might give more 
information about the exact mechanisms involved in glutathione-related Aβ42 neurotoxicity (Dalle-Donne 
et al. 2009; Franco & Cidlowski 2009). The death receptor RAGE is a neuronal and glial cell-surface 
receptor for advanced glycation end products (AEGs) and has been shown to be involved in promoting the 
perturbation of cellular functions that result in oxidative stress and cytotoxicity (Yan et al. 1996). 
Investigating how death receptors could be involved in this might be an additional interesting aspect. 
Another approach might be the examination of the oxidation status of Aβ42 in this model. Previous studies 
have shown that the oxidation of Aβ on Methionine 35 (MetOX) on the one hand can prevent the 
formation of Aβ aggregates by reducing hydrophobic and electrostatic associations, which leads to changes 
in structure during the initial stages of aggregation (Hou et al. 2004) and on the other hand can decrease 
the amount and length of Aβ40 and Aβ42 fibers in vitro (Gu & Viles 2016). I observed an increased life 
span of Aβ42 flies, when glutathione synthesis was decreased by downregulating Gclc via GclcRNAi 
(Figure 16A and A`). Maybe the lower levels of glutathione could result in more oxidation of Aβ42, which 
might lead to a decreased amount of Aβ42 fibers, which does not automatically must lead to less 
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neurotoxicity, but which could be an explanation of the observed increased life span of Aβ42 flies. 
Performing detailed structural analysis of Aβ42 in this model might be interesting for future studies. 
Whether an oxidative modification of Met35 in Aβ42 could positively affect the outcome of disease 
progression in AD or could have a beneficial effect on Aβ42 neurotoxicity in vivo, might also of interest in 
the future.  
One limitation of this study is that the neuronal glutathione redox potential could not be decreased 
significantly by any genetic or pharmacologic manipulation tested here. This could hint to a very tight 
control of this pathway in neurons and point out its important relevance. But this information might give 
us insights whether a decrease in glutathione redox potential could further increase survival or improve 
cognitive functions such as learning or memory, respectively. Additional investigation could also include 
the analysis of any cognitive decline in Aβ42 flies with and without Gclc-OE in order to test for a potential 
link between glutathione redox imbalance and redox-related cognitive dysfunction which would be very 
interesting to prospectively compare this with patient data. Deciphering the exact mechanism how the cell 
senses redox stress and translates it into downstream signaling events will be very exciting and of high 
importance to help combat AD. The developed models in this thesis offers the required in vivo tools to 
examine the link between glutathione redox potential and Aβ42 neurotoxicity in more detailed and 
provides stimulating insights into the relevance of redox signaling processes associated with 
neurodegeneration that will hopefully give spark for follow up studies. Importantly, this model provides a 
suitable platform to help finding strategies for therapeutic approaches and therefore can be used for 
clinical applications including drug screenings or screenings for genetic modifiers involved in redox-
associated mechanisms in AD. 
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7.  Abbrevations 
Aβ Amyloid-beta 
AD Alzheimer´s Disease 
AICD APP intracellular domain 
APP amyloid precursor protein 
BBB blood brain barrier 
BDSC Bloomington Drosophila Stock Center 
BSA Bovine Serum Albumin 
BSO Buthionine Sulfoximine 
DA Diamide 
DEM Diethyl maleate 
DMSO Dimethyl sulfoxide 
DR dynamic range 
DTT Dithiothreitol 
EDTA Ethylenediaminetetraacetic acid 
EGSH glutathione redox potential 
ELISA enzyme-linked immunosorbent assay 
FBS Fetal bovine serum 
FTD Frontotemporal dementia 
Gclc glutamate cysteine ligase catalytic subunit 
GdnHCl Guanidine hydrochloride 
GFP green fluorescent protein 
Grx1 glutaredoxin 1 
GSH reduced glutathione 
GSSG oxidized glutathione 
JNK c-Jun N-terminal Kinase 
LSM Laser Scanning Microscope 
MCI mild cognitive impairment 
NAC N-acetyl-L-cysteine 
NaN not a number 
NDGA Nordihydroguaiaretic acid 
NEM N-ethyl maleimide 
NFTs neurofibrillary tangles 
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Nrf2 NF-E2-related factor-2 
dNTPs Nucleoside triphosphate 
n.s. not significant 
OE overexpression 
Orp1 oxidant receptor peroxidase 1 
OxD degree of oxidation 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
p-FTAA pentamer formyl thiophene acetic acid 
RNAi RNA interference 
roGFP reduction-oxidation sensitive green fluorescent protein 
RT room temperature 
SDS Sodium dodecyl sulfate 
s.e.m. standard error of the mean 
SOD1/2 Superoxide dismutase 1/2 
TAβ Tandem Amyloid-beta 
tBHQ tert-Butylhydroquinone 
TCA L-4-Thiazolidinecarboxylic acid 
ThS Thioflavin S 
UAS Upstream Activating Sequence 
VDRC Vienna Drosophila Resource Center 
v/v volume/volume 
w/v weight/volume 
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10.  Supplementary 
10.1 The degree of probe oxidation in neurons upon Aβ accumulation 
 
 
 
Figure 21: The degree of probe oxidation in neurons upon Aβ accumulation. Redox analysis with the cytosolic 
glutathione redox sensor (cyto-Grx1-roGFP2) in neurons, under the control of the nSyb-Gal4 promoter was 
performed in a time course (day 3, 6, 9, 12; n = 3-6 fly brains per time point and genotype). The graph represents 
the degree of probe oxidation of the cyto-Grx1-roGFP2 sensor. All error bars indicate s.e.m. Statistical analysis was 
performed with one-way ANOVA. *p ≤ 0,05, ***p ≤ 0.001, ****p ≤ 0.0001. 
 
 
  
Supplementary 
 
92 
 
 
 
 
List of Publications 
 
 93 
11.  List of Publications 
1.  Yao V. Zhang, Shabab B. Hannan, Zeenna A. Stapper, Jeannine V. Kern, Thomas R. 
Jahn, Tobias M. Rasse. The Drosophila KIF1A Homolog unc-104 Is Important for Site-
Specific Synapse Maturation. Front. Cell. Neurosci. (2016) 10:207. Epub 2016 Sep 5. 
 
2.  Zeenna A. Stapper, Thomas R. Jahn. Changes in glutathione redox potential are linked to 
Aβ42-induced neurotoxicity. Manuscript in revision in Cell Reports 
 
 
  
List of Publications 
 
94 
 
 
 
Acknowledgements 
 
 95 
12.  Acknowledgements 
At this point I would like to thank all the people who supported me during my PhD. Especially, I want to 
thank Dr. Thomas R. Jahn. Thank you for bringing me into your team, giving me the opportunity to 
work on such an interesting topic and supporting me to become an independently working scientist, as I 
probably will call myself officially, when I hopefully pass my last PhD exam ;). I am thankful to my TAC 
members Prof. Dr. Bernd Bukau and PD Dr. Tobias P. Dick. Thank you for supporting my project 
through all this time, always giving me helpful feedback and advice through the challenging times. In 
particular, thank you for offering me a working place in your group after our lab closed. I highly 
appreciate your overall support and your comments on the manuscript. A big thank you to Dr. Björn 
Tews for hosting me in your lab for three months and supporting me to get a contract extension. Thank 
you to the Schaller Labs for keeping me store my bench equipment in your lab spaces as long as I needed 
it. Another big thank you to Prof. Dr. Aurelio Teleman for giving your feedback and support not only as 
deputy of our lab for the last year it officially existed but also as my referee for writing my reference letter. 
I would also like to thank Dr. Valéry Grinevich for joining the examination committee. Thank you to the 
Chica & Heinz Schaller Foundation, the DFKZ Heidelberg, and the Faculty of Biosciences at the 
University of Heidelberg for supporting my PhD. I strongly thank Lindsay Murrells and the Helmholtz 
International Graduate School for Cancer Research for your financial support in the last period of my 
PhD and for the excellent PhD program. A special thank you also to PD Tobias P. Dick, Prof. W.C. Orr, 
Dr. A. J. Whitworth, Prof. Dr. M. Boutros and Dr. D. Bohmann for providing reagents and fly lines. I 
also thank the University of Cambridge Department of Genetics Fly Facility and the Imaging Core 
Facility (DKFZ Heidelberg) for technical support. In addition I would like to thank Dr. Ana Barata for 
introducing me to the work with the redox sensors.  
Thank you Fappy Lab aka Happy Lab. You all immediately welcomed me on the first day. Every one of 
you enriched my life in many different ways. I especially enjoyed our numerous valuable scientific and 
non-scientific discussions most memorable in the S1, fly room or at P11. I learned a lot from you and I 
am very happy that I met you. A special thank you also to my friends and my old high school crew, who 
supported me, distracted me and especially lightened my day whenever I needed it. I am happy to have 
you in my life, some for over 28 years and others for just a few, but more to come % At the end, I want to 
thank you mum for all your positivity and optimism and for something that influenced my personality a 
lot: setting the example to always believe in the good.  
Finally, I want to thank you Jan for all your love and support and of course for the preparation of the 
schematic drawings of the neurons and glia cells ;) Thank you for accompanying me through all my life. 
We went through a lot of challenges and strokes of fate. But together we were strong and have overcome 
them all. Jan, you are my love, my anchor, my best friend and my home. I am really looking forward to 
what´s to come % 
  
 
 
 
  
 
 
 
  
 
 
